<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1220" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1220/" /><meta name="ncbi_pagename" content="Tuberous Sclerosis Complex - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Tuberous Sclerosis Complex - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Tuberous Sclerosis Complex" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/07/12" /><meta name="citation_author" content="Hope Northrup" /><meta name="citation_author" content="Mary Kay Koenig" /><meta name="citation_author" content="Deborah A Pearson" /><meta name="citation_author" content="Kit Sing Au" /><meta name="citation_pmid" content="20301399" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1220/" /><meta name="citation_keywords" content="Bourneville Disease" /><meta name="citation_keywords" content="Bourneville Disease" /><meta name="citation_keywords" content="Hamartin" /><meta name="citation_keywords" content="Tuberin" /><meta name="citation_keywords" content="TSC1" /><meta name="citation_keywords" content="TSC2" /><meta name="citation_keywords" content="Tuberous Sclerosis Complex" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Tuberous Sclerosis Complex" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Hope Northrup" /><meta name="DC.Contributor" content="Mary Kay Koenig" /><meta name="DC.Contributor" content="Deborah A Pearson" /><meta name="DC.Contributor" content="Kit Sing Au" /><meta name="DC.Date" content="2018/07/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1220/" /><meta name="description" content="Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical dysplasias, and subependymal giant cell astrocytomas [SEGAs], seizures, intellectual disability / developmental delay, psychiatric illness); kidney (angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system tumors are the leading cause of morbidity and mortality; renal disease is the second leading cause of early death." /><meta name="og:title" content="Tuberous Sclerosis Complex" /><meta name="og:type" content="book" /><meta name="og:description" content="Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical dysplasias, and subependymal giant cell astrocytomas [SEGAs], seizures, intellectual disability / developmental delay, psychiatric illness); kidney (angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system tumors are the leading cause of morbidity and mortality; renal disease is the second leading cause of early death." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1220/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/tuberous-sclerosis/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1220/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88BE0BE03F9B7100000000071E0291.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1220_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1220_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/spg20/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tubulin-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1220_"><span class="title" itemprop="name">Tuberous Sclerosis Complex</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Bourneville Disease</div><p class="contrib-group"><span itemprop="author">Hope Northrup</span>, MD, FACMG, <span itemprop="author">Mary Kay Koenig</span>, MD, <span itemprop="author">Deborah A Pearson</span>, PhD, and <span itemprop="author">Kit Sing Au</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1220_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1220_ai__"><div class="contrib half_rhythm"><span itemprop="author">Hope Northrup</span>, MD, FACMG<div class="affiliation small">Department of Pediatrics<br />Division of Medical Genetics<br />McGovern Medical School<br />University of Texas Health Science Center at Houston<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmt.htu@purhtron.epoh" class="oemail">ude.cmt.htu@purhtron.epoh</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mary Kay Koenig</span>, MD<div class="affiliation small">Division of Child and Adolescent Neurology<br />Department of Pediatrics<br />McGovern Medical School<br />University of Texas Health Science Center at Houston<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmt.htu@gineok.k.yram" class="oemail">ude.cmt.htu@gineok.k.yram</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Deborah A Pearson</span>, PhD<div class="affiliation small">Department of Psychiatry and Behavioral Sciences<br />Division of Child and Adolescent Psychiatry<br />McGovern Medical School<br />University of Texas Health Science Center at Houston<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmt.htu@nosraep.a.harobed" class="oemail">ude.cmt.htu@nosraep.a.harobed</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kit Sing Au</span>, PhD<div class="affiliation small">Department of Pediatrics<br />Division of Medical Genetics<br />McGovern Medical School<br />University of Texas Health Science Center at Houston<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmt.htu@ua.gnis-tik" class="oemail">ude.cmt.htu@ua.gnis-tik</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 13, 1999</span>; Last Update: <span itemprop="dateModified">July 12, 2018</span>.</p><p><em>Estimated reading time: 41 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="tuberous-sclerosis.Summary" itemprop="description"><h2 id="_tuberous-sclerosis_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical dysplasias, and subependymal giant cell astrocytomas [SEGAs], seizures, intellectual disability / developmental delay, psychiatric illness); kidney (angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system tumors are the leading cause of morbidity and mortality; renal disease is the second leading cause of early death.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of TSC is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>one of the following</i>:</p><ul><li class="half_rhythm"><div>Two major clinical features</div></li><li class="half_rhythm"><div>One major clinical feature and two or more minor features</div></li><li class="half_rhythm"><div>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TSC1</i> or <i>TSC2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> For enlarging SEGAs: mTOR inhibitors; neurosurgery when size causes life-threatening neurologic symptoms. For seizures: vigabatrin and other antiepileptic drugs, and on occasion, epilepsy surgery. For renal angiomyolipomas &#x0003e;4 cm, or &#x0003e;3 cm and growing rapidly: mTOR inhibitors are the recommended first line of therapy with secondary therapy options being embolization, renal sparing surgery, or ablative therapy. For facial angiofibromas: topical mTOR inhibitors. For symptomatic cardiac rhabdomyomas: surgical intervention or consideration of mTOR inhibitor therapy. For LAM: mTOR inhibitors.</p><p><i>Prevention of secondary complications:</i> For those on vigabatrin therapy, vision testing within four weeks of therapy initiation, at three-month intervals while on treatment, and three to six months after treatment is discontinued.</p><p><i>Surveillance:</i> Brain MRI every one to three years in asymptomatic individuals with TSC younger than age 25 years to monitor for new occurrence of SEGAs; those with asymptomatic SEGA in childhood should continue to be imaged periodically in adulthood; for those with large or growing SEGA or SEGA causing ventricular enlargement, more frequent brain MRIs as deemed clinically appropriate; screening for TSC-associated neuropsychiatric disorder (TAND) at least annually with comprehensive formal evaluation for TAND at key developmental time points; EEG in individuals with known or suspected seizure activity; MRI of the abdomen to assess for progression of angiomyolipoma and renal cystic disease every one to three years; assess renal function (glomerular filtration rate and blood pressure) at least annually; echocardiogram every one to three years in asymptomatic infants and children with cardiac rhabdomyomas until regression is documented; clinical screening for LAM symptoms (exertional dyspnea and shortness of breath) at each clinic visit in women older than age 18 years or those who report respiratory symptoms; high-resolution computed tomography (HRCT) every five to ten years in asymptomatic individuals at risk for LAM (adult females age &#x0003e;18 years) even when there are no signs of LAM on baseline examination; annual pulmonary function testing and HRCT every two to three years for individuals with lung cysts detected by HRCT; annual dermatologic examination; dental examination every six months; annual ophthalmology evaluation in those with previously identified ophthalmologic lesions or vision symptoms.</p><p><i>Agents/circumstances to avoid:</i> Smoking; estrogen use; nephrectomy.</p><p><i>Evaluation of relatives at risk:</i> Identifying <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> relatives enables monitoring for early detection of problems associated with TSC, which leads to earlier treatment and better outcomes.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>TSC is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Two thirds of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have TSC as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The offspring of an affected individual are at a 50% risk of inheriting the pathogenic variant. If the pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="tuberous-sclerosis.Diagnosis"><h2 id="_tuberous-sclerosis_Diagnosis_">Diagnosis</h2><div id="tuberous-sclerosis.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Tuberous sclerosis complex (TSC) <b>should be suspected</b> in individuals with either one major clinical feature or two or more minor features, as listed below.</p><p><b>Major features</b></p><ul><li class="half_rhythm"><div>Angiofibromas (&#x02265;3) or fibrous cephalic plaque</div></li><li class="half_rhythm"><div>Cardiac rhabdomyoma</div></li><li class="half_rhythm"><div>Cortical dysplasias, including tubers and cerebral white matter migration lines</div></li><li class="half_rhythm"><div>Hypomelanotic macules (3 to &#x0003e;5 mm in diameter)</div></li><li class="half_rhythm"><div>Lymphangioleiomyomatosis (LAM) (see <a href="#tuberous-sclerosis.Establishing_the_Diag">*Note</a>)</div></li><li class="half_rhythm"><div>Multiple retinal nodular hamartomas</div></li><li class="half_rhythm"><div>Renal angiomyolipoma (see <a href="#tuberous-sclerosis.Establishing_the_Diag">*Note</a>)</div></li><li class="half_rhythm"><div>Shagreen patch</div></li><li class="half_rhythm"><div>Subependymal giant cell astrocytoma (SEGA)</div></li><li class="half_rhythm"><div>Subependymal nodules (SENs)</div></li><li class="half_rhythm"><div>Ungual fibromas (&#x02265;2)</div></li></ul><p><b>Minor features</b></p><ul><li class="half_rhythm"><div>"Confetti" skin lesions (numerous 1- to 3-mm hypopigmented macules scattered over regions of the body such as the arms and legs)</div></li><li class="half_rhythm"><div>Dental enamel pits (&#x0003e;3)</div></li><li class="half_rhythm"><div>Intraoral fibromas (&#x02265;2)</div></li><li class="half_rhythm"><div>Multiple renal cysts</div></li><li class="half_rhythm"><div>Nonrenal hamartomas</div></li><li class="half_rhythm"><div>Retinal achromic patch</div></li></ul></div><div id="tuberous-sclerosis.Establishing_the_Diag"><h3>Establishing the Diagnosis</h3><p>Clinical diagnostic criteria for TSC have been revised [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>] to take into account the results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>A <b>definite</b> diagnosis of TSC <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with EITHER of the following:</p><ul><li class="half_rhythm"><div>Two major features (see *Note) or one major feature with two or more minor features</div></li><li class="half_rhythm"><div>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in either <i>TSC1</i> or <i>TSC2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.molecular_genetic_t/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTmoleculargenetict" rid-ob="figobtuberoussclerosisTmoleculargenetict">Table 1</a>)</div></li></ul><p><b>*</b>Note: The combination of LAM and angiomyolipomas without other features does not meet the clinical diagnostic criteria for a definite diagnosis.</p><p>Molecular genetic testing approaches can include <b>concurrent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Concurrent <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>TSC1 and TSC2.</i></div><div class="half_rhythm">Note: If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for a pathogenic variant should be considered [<a class="bk_pop" href="#tuberous-sclerosis.REF.qin.2010.573">Qin et al 2010</a>; <a class="bk_pop" href="#tuberous-sclerosis.REF.nellist.2015.10">Nellist et al 2015</a>; Authors, personal observation]. For more information on somatic mosaicism as a cause of TSC click <a href="/books/NBK1220/bin/tuberous-sclerosis-mosaicism.pdf">here</a> (pdf).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TSC1, TSC2</i> and other genes of interest (see <a href="#tuberous-sclerosis.Differential_Diagnosi">Differential Diagnosis</a>) may be considered to identify the genetic cause when the diagnosis of TSC is less certain in order to limit cost and limit identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.molecular_genetic_t/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTmoleculargenetict" rid-ob="figobtuberoussclerosisTmoleculargenetict">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="tuberous-sclerosis.T.molecular_genetic_t" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Tuberous Sclerosis Complex (TSC)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.T.molecular_genetic_t/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.T.molecular_genetic_t_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of TSC Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>3</sup> Detected by Gene, Family History, &#x00026; Method</th></tr><tr><th headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4" id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Familial cases</th><th headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4" id="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Simplex cases&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TSC1</i></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~26%&#x000a0;<sup>5</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>6,&#x000a0;7</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~9.8%</td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~15.5%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>8</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~0.1%&#x000a0;<sup>9</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~0.5%&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TSC2</i></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~69%&#x000a0;<sup>5</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>6</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13.8%</td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~53%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>8,&#x000a0;10</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~0.2%&#x000a0;<sup>9</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~2%&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%&#x000a0;<sup>11,&#x000a0;12</sup></td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_1_4 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_1 hd_h_tuberous-sclerosis.T.molecular_genetic_t_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tuberous-sclerosis.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd><dt>2. </dt><dd><div id="tuberous-sclerosis.TF.1.2"><p class="no_margin">See <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="tuberous-sclerosis.TF.1.3"><p class="no_margin">See <a href="#tuberous-sclerosis.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="tuberous-sclerosis.TF.1.4"><p class="no_margin">Simplex case = single occurrence in a family</p></div></dd><dt>5. </dt><dd><div id="tuberous-sclerosis.TF.1.5"><p class="no_margin">Of the more than 10,000 individuals with TSC and their families in whom pathogenic variants have been identified, ~26% of probands had a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TSC1</i> and ~74% had a pathogenic variant in <i>TSC2</i> [<a class="bk_pop" href="#tuberous-sclerosis.REF.jones.1999.1305">Jones et al 1999</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.dabora.2001.64">Dabora et al 2001</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2004.699">Au et al 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.sancak.2005.731">Sancak et al 2005</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.tyburczy.2015">Tyburczy et al 2015</a>] (see <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>, TSC databases).</p></div></dd><dt>6. </dt><dd><div id="tuberous-sclerosis.TF.1.6"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>7. </dt><dd><div id="tuberous-sclerosis.TF.1.7"><p class="no_margin"><i>TSC1</i> pathogenic variants are primarily small deletions and insertions and pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></dd><dt>8. </dt><dd><div id="tuberous-sclerosis.TF.1.8"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>9. </dt><dd><div id="tuberous-sclerosis.TF.1.9"><p class="no_margin">Comparing methods to identify large (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>/<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions in 65 individuals with TSC, <a class="bk_pop" href="#tuberous-sclerosis.REF.rendtorff.2005.374">Rendtorff et al [2005]</a> concluded that multiple ligation-dependent probe amplification (MLPA) is more sensitive than <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis and long-range <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>. Using MLPA, they identified large <i>TSC2</i> exon or whole-gene deletions in four of 15 families in which no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had been identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and Southern blotting.</p></div></dd><dt>10. </dt><dd><div id="tuberous-sclerosis.TF.1.10"><p class="no_margin"><i>TSC2</i> pathogenic variants include significant numbers of large (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> and whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) deletions and rearrangements that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of exons and thus require gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> for detection.</p></div></dd><dt>11. </dt><dd><div id="tuberous-sclerosis.TF.1.11"><p class="no_margin"><a class="bk_pop" href="#tuberous-sclerosis.REF.sancak.2005.731">Sancak et al [2005]</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al [2007]</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kwiatkowski.2010">Kwiatkowski [2010]</a>, <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>, TSC databases</p></div></dd><dt>12. </dt><dd><div id="tuberous-sclerosis.TF.1.12"><p class="no_margin">Inferring from the 5% detection rate for <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> [<a class="bk_pop" href="#tuberous-sclerosis.REF.kozlowski.2007.389">Kozlowski et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.qin.2010.573">Qin et al 2010</a>] among 15% of individuals with TSC who do not have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in <i>TSC1</i> or <i>TSC2</i> by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, the authors conclude that at least 1% of persons with TSC have somatic mosaicism for a <i>TSC1</i> or <i>TSC2</i> pathogenic variant [Author, personal observation].</p></div></dd></dl></div></div></div></div></div><div id="tuberous-sclerosis.Clinical_Characterist"><h2 id="_tuberous-sclerosis_Clinical_Characterist_">Clinical Characteristics</h2><div id="tuberous-sclerosis.Clinical_Description"><h3>Clinical Description</h3><p>Tuberous sclerosis complex (TSC) exhibits both inter- and <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> in clinical findings. Females tend to have milder disease than males [<a class="bk_pop" href="#tuberous-sclerosis.REF.sancak.2005.731">Sancak et al 2005</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al 2007</a>]. Any organ system can be involved in TSC.</p><div id="tuberous-sclerosis.Skin"><h4>Skin</h4><p>The skin is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in virtually 100% of individuals with TSC. Skin lesions include: hypomelanotic macules (~90% of individuals), confetti skin lesions (frequency varies widely from 3% of children to &#x02264;58% overall), facial angiofibromas (~75%), shagreen patches (~50%), fibrous cephalic plaques, and ungual fibromas (20% overall but &#x02264;80% in older affected adults) [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>]. Among the skin lesions, the facial angiofibromas cause the most disfigurement. None of the skin lesions results in serious medical problems.</p></div><div id="tuberous-sclerosis.Central_Nervous_Syste"><h4>Central Nervous System (CNS)</h4><p>CNS tumors are the leading cause of morbidity and mortality in TSC. The brain lesions of TSC, including subependymal nodules (SENs), cortical dysplasias, and subependymal giant cell astrocytomas (SEGAs), can be distinguished with neuroimaging studies. SENs occur in 80% of individuals and cortical dysplasias in approximately 90%. SEGAs occur in 5%-15% of all individuals with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>]. These giant cell astrocytomas may enlarge, causing pressure and obstruction and resulting in significant morbidity and mortality.</p></div><div id="tuberous-sclerosis.Seizures"><h4>Seizures</h4><p>More than 80% of individuals with TSC have been reported to have seizures, although this percentage may reflect ascertainment bias of more severely involved individuals. TSC is a known cause of infantile spasms. At least 50% of individuals have developmental delay or intellectual disability. The leading cause of premature death (32.5%) among individuals with TSC is a complication of severe intellectual disability (e.g., status epilepticus and bronchopneumonia) [<a class="bk_pop" href="#tuberous-sclerosis.REF.shepherd.1991.792">Shepherd et al 1991</a>].</p></div><div id="tuberous-sclerosis.TSCAssociated_Neurops"><h4>TSC-Associated Neuropsychiatric Disorder (TAND)</h4><p>TAND refers to the interrelated functional and clinical manifestations of brain dysfunction common in individuals with TSC, including behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.a">de Vries 2010a</a>]. Although more than 90% of children and adults with TSC will experience one or more TAND concerns in their lifetime, only 20% ever receive evaluation and intervention for them [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.2013.618">Krueger 2013</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2015.25">de Vries et al 2015</a>].</p><p><b>Autism spectrum disorder (ASD).</b> Individuals with TSC are at high risk for ASD, with estimates running from 16% to 61% [<a class="bk_pop" href="#tuberous-sclerosis.REF.gillberg.1994.50">Gillberg et al 1994</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.bolton.2002.1247">Bolton et al 2002</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.wong.2006.199">Wong 2006</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2007.16">de Vries et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.chung.2011.263">Chung et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.numis.2011.981">Numis et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.spurling_jeste.2014.160">Spurling Jeste et al 2014</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>], compared to a less than 2% risk in the general population (see Centers for Disease Control and Prevention: <a href="https://www.cdc.gov/ncbddd/autism/data.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Autism Spectrum Disorder Data &#x00026; Statistics</a>). Signs of ASD in individuals with TSC emerge as early as age nine months [<a class="bk_pop" href="#tuberous-sclerosis.REF.mcdonald.2017.1981">McDonald et al 2017</a>]. Individuals with TSC who have subependymal giant cell astrocytomas are nearly twice as likely to have ASD [<a class="bk_pop" href="#tuberous-sclerosis.REF.kothare.2014.1025">Kothare et al 2014</a>], and treatment with everolimus has been found to reduce SEGA size, seizures, and features of ASD [<a class="bk_pop" href="#tuberous-sclerosis.REF.hwang.2016.56">Hwang et al 2016</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kilincaslan.2017.383">Kilincaslan et al 2017</a>]. Neurofunctional impairments closely associated with ASD, including impaired language pathways [<a class="bk_pop" href="#tuberous-sclerosis.REF.lewis.2013.1526">Lewis et al 2013</a>] and atypical face processing [<a class="bk_pop" href="#tuberous-sclerosis.REF.spurling_jeste.2014.160">Spurling Jeste et al 2014</a>], have been noted in persons with TSC. Children with TSC and ASD are at higher risk for global cognitive impairment than are children with TSC who do not have ASD [<a class="bk_pop" href="#tuberous-sclerosis.REF.jeste.2008.520">Jeste et al 2008</a>]. The ASD profile in toddlers with TSC has been found to have "complete convergence" with young children with nonsyndromic ASD [<a class="bk_pop" href="#tuberous-sclerosis.REF.jeste.2016.766">Jeste et al 2016</a>].</p><p><b>Attention deficit hyperactivity disorder (ADHD)</b> is another common (and potentially seriously debilitating) condition closely associated with TSC. Estimates of ADHD prevalence in individuals with TSC range from 21% to 50% [<a class="bk_pop" href="#tuberous-sclerosis.REF.gillberg.1994.50">Gillberg et al 1994</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.prather.2004.666">Prather &#x00026; de Vries 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.muzykewicz.2007.506">Muzykewicz et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kopp.2008.505">Kopp et al 2008</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.chung.2011.263">Chung et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>]. Deficits in attention (particularly in dual-task performance), cognitive flexibility, and memory have also been noted in neuropsychological studies of children and adults with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.ridler.2007.261">Ridler et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2009.387">de Vries et al 2009</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.tierney.2011.437">Tierney et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.curatolo.2015.733">Curatolo et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2015.25">de Vries et al 2015</a>].</p><p><b>Learning and cognitive impairment.</b> Individuals with TSC are at high risk for having intellectual disability, with prevalence rates estimated between 44% and 64% [<a class="bk_pop" href="#tuberous-sclerosis.REF.joinson.2003.335">Joinson et al 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.goh.2005.235">Goh et al 2005</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.van_eeghen.2012.510">van Eeghen et al 2012</a>].</p><ul><li class="half_rhythm"><div>Approximately 36%-58% of children with TSC have serious academic difficulties (e.g., learning disabilities) requiring intervention [<a class="bk_pop" href="#tuberous-sclerosis.REF.curatolo.2015.733">Curatolo et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2010b.275">de Vries 2010b</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>].</div></li><li class="half_rhythm"><div>The risk of learning and cognitive impairment increases significantly if seizure activity is not controlled. A number of investigations have demonstrated that a history of infantile spasms (IS) and/or poor seizure control in general is associated with lower intellectual ability [<a class="bk_pop" href="#tuberous-sclerosis.REF.joinson.2003.335">Joinson et al 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.goh.2005.235">Goh et al 2005</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.bolton.2015.2321">Bolton et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.capal.2017.245">Capal et al 2017</a>]. In a small sample (n=6), <a class="bk_pop" href="#tuberous-sclerosis.REF.humphrey.2014.108">Humphrey et al [2014]</a> demonstrated a dramatic dose-dependent relationship between seizure activity and intellectual impairment: estimated intelligence quotient (IQ) dropped from 92 (prior to IS) to 73 (if IS duration was &#x0003c;1 month) to 62 (if IS duration was &#x0003e;1 month). These findings underscore the crucial need for adequate seizure control in individuals with TSC.</div></li></ul><p><b>Disruptive behaviors and emotional problems</b> are another cluster of debilitating conditions associated with TSC. Aggression has been noted in many individuals with TSC (13%-58%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2007.16">de Vries et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kopp.2008.505">Kopp et al 2008</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.staley.2008.650">Staley et al 2008</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.chung.2011.263">Chung et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.eden.2014.10">Eden et al 2014</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.wilde.2017.119">Wilde et al 2017</a>] as has self-injurious behavior (27%-41%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2007.16">de Vries et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.eden.2014.10">Eden et al 2014</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.wilde.2017.119">Wilde et al 2017</a>]. Individuals with TSC are also at high risk for anxiety (9%-48%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2007.16">de Vries et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.muzykewicz.2007.506">Muzykewicz et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kopp.2008.505">Kopp et al 2008</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.chung.2011.263">Chung et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>] and depression (6%-43%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2015.25">de Vries et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kingswood.2017.2">Kingswood et al 2017</a>].</p><p><b>Assessment.</b> All individuals with TSC should be assessed for the presence of TAND, given that it has been closely associated with clinical outcome and quality of life [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.2013.618">Krueger 2013</a>]. The <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427347/bin/NIHMS685072-supplement-TAND_Checklist.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TAND Checklist</a> [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2015.25">de Vries et al 2015</a>], a simple paper-and-pencil screening questionnaire available at no cost, is a promising tool to address the significant gap between clinical need associated with TAND and those receiving intervention for these needs [<a class="bk_pop" href="#tuberous-sclerosis.REF.de_vries.2015.25">de Vries et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.leclezio.2015.113">Leclezio &#x00026; de Vries 2015</a>]. Given that unaddressed TAND concerns contribute significantly to poor outcome, and that individuals with TSC have a very high health care resource utilization [<a class="bk_pop" href="#tuberous-sclerosis.REF.lennert.2013.461">Lennert et al 2013</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.rentz.2015.435">Rentz et al 2015</a>], the importance of recognizing and addressing TAND concerns cannot be overestimated.</p></div><div id="tuberous-sclerosis.Kidneys"><h4>Kidneys</h4><p>Renal disease is the second leading cause of early death (27.5%) in individuals with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.shepherd.1991.792">Shepherd et al 1991</a>]. An estimated 80% of children with TSC have an identifiable renal lesion by a mean age of 10.5 years [<a class="bk_pop" href="#tuberous-sclerosis.REF.ewalt.1998.141">Ewalt et al 1998</a>].</p><p>Five different renal lesions occur in TSC: benign angiomyolipoma (70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals); epithelial cysts (20%-30%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.sancak.2005.731">Sancak et al 2005</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al 2007</a>]; oncocytoma (benign adenomatous hamartoma) (&#x0003c;1%); malignant angiomyolipoma (&#x0003c;1%); and renal cell carcinoma (&#x0003c;3%) [<a class="bk_pop" href="#tuberous-sclerosis.REF.patel.2005.665">Patel et al 2005</a>].</p><p><b>Benign angiomyolipomas</b> comprise abnormal blood vessels, sheets of smooth muscle, and mature adipose tissue. In children, angiomyolipomas tend to increase in size or number over time. Benign angiomyolipomas can cause life-threatening bleeding and can replace renal parenchyma, leading to end-stage renal disease (ESRD).</p><p><b>Renal cysts</b> have an epithelial lining of hypertrophic hyperplastic eosinophilic cells. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have features of both TSC caused by <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>TSC2</i> and <a href="/books/n/gene/pkd-ad/">autosomal dominant polycystic kidney disease</a> (ADPKD) caused by deletion of <i>PKD1</i>. In these individuals, progressive enlargement of the cysts may compress functional parenchyma and lead to ESRD [<a class="bk_pop" href="#tuberous-sclerosis.REF.martignoni.2002.198">Martignoni et al 2002</a>]. Individuals with the <i>TSC2/PKD1</i> <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion-syndrome/">contiguous gene deletion syndrome</a> are also at risk of developing the complications of ADPKD, which include cystic lesions in other organs (e.g., the liver) and Berry aneurysms.</p><p><b>Malignant angiomyolipoma</b> and <b>renal cell carcinoma</b> (RCC) may result in death. Although rare, these two tumors are much more common in individuals with TSC than in the general population [<a class="bk_pop" href="#tuberous-sclerosis.REF.pea.1998.180">Pea et al 1998</a>]. It is estimated that 2%-5% of persons with TSC will develop RCC. The age of diagnosis of RCC in those with TSC is 28-30 years &#x02013; much earlier than the age of diagnosis for <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> RCC [<a class="bk_pop" href="#tuberous-sclerosis.REF.crino.2006.1345">Crino et al 2006</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.borkowska.2011.13">Borkowska et al 2011</a>]. Note: Common imaging techniques may not distinguish fat-poor angiomyolipomas from RCC. Immunologic staining for HMB-45 for angiomyolipomas and cytokeratin for RCC is recommended.</p></div><div id="tuberous-sclerosis.Heart"><h4>Heart</h4><p>Cardiac rhabdomyomas are present in 47%-67% of individuals with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.jones.1999.1305">Jones et al 1999</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.dabora.2001.64">Dabora et al 2001</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.sancak.2005.731">Sancak et al 2005</a>]. These tumors have been documented to regress with time and eventually disappear. The cardiac rhabdomyomas are often largest during the neonatal period. If cardiac outflow obstruction does not occur at birth, the individual is unlikely to have health problems from these tumors later. However, a small number of individuals have arrhythmias postulated to result from rests of persistent cells left after the rhabdomyomas regress. For information regarding treatment options for obstructive lesions, see <a href="#tuberous-sclerosis.Management">Management</a>.</p></div><div id="tuberous-sclerosis.Lung"><h4>Lung</h4><p><b>Lymphangioleiomyomatosis (LAM)</b> of the lung primarily affects women and has been estimated to occur in approximately 30%-40% of females with TSC; however, a recent study suggests that the diagnosis of LAM is age dependent and occurs in up to 80% of women with TSC by age 40 years [<a class="bk_pop" href="#tuberous-sclerosis.REF.adriaensen.2011.625">Adriaensen et al 2011</a>]. Approximately 5%-10% of women with TSC present with symptomatic LAM [<a class="bk_pop" href="#tuberous-sclerosis.REF.henske.2016.16035">Henske et al 2016</a>]. Cystic findings consistent with LAM are observed in 10%-12% of males with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>].</p><ul><li class="half_rhythm"><div>The mean age of diagnosis for LAM in those with TSC is 28 years, compared to 35 years for <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> LAM.</div></li><li class="half_rhythm"><div>Individuals with TSC-associated LAM as well as <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> LAM may present with shortness of breath or hemoptysis. Chest radiographs reveal a diffuse reticular pattern and CT examination shows diffuse interstitial changes with infiltrates and cystic changes. Pneumothorax and chylothorax may occur in individuals <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by LAM. Some individuals progress to respiratory failure and death.</div></li><li class="half_rhythm"><div>It is suggested that LAM associated with TSC is milder than <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> LAM because persons with TSC and LAM account for only about 15% of registrants in the <a href="http://www.thelamfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NHLBI LAM Foundation</a> [<a class="bk_pop" href="#tuberous-sclerosis.REF.mccormack.2008.507">McCormack 2008</a>]. Furthermore, persons with TSC and LAM have less severe lung cysts than persons with sporadic LAM [<a class="bk_pop" href="#tuberous-sclerosis.REF.avila.2007.277">Avila et al 2007</a>].</div></li></ul><p><b>Multifocal micronodular pneumonocyte hyperplasia (MMPH)</b>, characterized by multiple nodular proliferations of type II pneumocytes, was first described in association with TSC in 1991 [<a class="bk_pop" href="#tuberous-sclerosis.REF.popper.1991.347">Popper et al 1991</a>]. While MMPH does not have known prognostic or physiologic consequences, there have been at least two reports of respiratory failure associated with MMPH [<a class="bk_pop" href="#tuberous-sclerosis.REF.cancellieri.2002.263">Cancellieri et al 2002</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.kobashi.2008.1076">Kobashi et al 2008</a>]. The precise prevalence of MMPH in individuals with TSC is not known but may be as high as 40%-58% [<a class="bk_pop" href="#tuberous-sclerosis.REF.franz.2001.661">Franz et al 2001</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.muzykewicz.2009.465">Muzykewicz et al 2009</a>]. There is no gender predilection and MMPH may occur in the presence or absence of LAM in persons with TSC. MMPH can be confused with atypical adenomatous hyperplasia, which is a premalignant lesion that is not clearly associated with TSC.</p></div><div id="tuberous-sclerosis.Eye"><h4>Eye</h4><p>The retinal lesions of TSC include hamartomas (elevated mulberry lesions or plaque-like lesions) observed in 30%-50% of individuals with TSC. These lesions are relatively rare in the general population with a recent case series of 3573 healthy term newborns identifying only two with these lesions [<a class="bk_pop" href="#tuberous-sclerosis.REF.li.2013.588">Li et al 2013</a>]. Achromic patches (similar to the hypopigmented skin lesions) have been noted to occur in 39% of individuals with TSC, while the general population incidence is 1:20,000 [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.1993.41">Northrup et al 1993</a>]. Although these lesions are usually asymptomatic, a few persons with TSC have had progressively enlarging retinal astrocytic hamartomas with total exudative retinal detachment and neovascular glaucoma [<a class="bk_pop" href="#tuberous-sclerosis.REF.shields.2004.139">Shields et al 2004</a>].</p></div><div id="tuberous-sclerosis.Extrarenal_Angiomyoli"><h4>Extrarenal Angiomyolipomas (AMLs)</h4><p>Although rare, extrarenal angiomyolipomas have been reported [<a class="bk_pop" href="#tuberous-sclerosis.REF.elsayes.2005.80">Elsayes et al 2005</a>]. In a retrospective study of sonographic and CT images, <a class="bk_pop" href="#tuberous-sclerosis.REF.fricke.2004.1027">Fricke et al [2004]</a> identified eight hepatic AMLs in 62 individuals with TSC (13%).</p></div><div id="tuberous-sclerosis.Neuroendocrine_Tumors"><h4>Neuroendocrine Tumors (NETs)</h4><p><a class="bk_pop" href="#tuberous-sclerosis.REF.dworakowska.2009.45">Dworakowska &#x00026; Grossman [2009]</a> summarized case reports of persons with TSC who had NETs; the majority of tumors were pituitary adenomas (ACTHoma and GHoma), parathyroid adenomas and hyperplasia, and pancreatic adenomas (insulinoma and islet cell neoplasm). More recently single case reports have included gastrinoma, pheochromocytoma, and carcinoids. Several individuals had a <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and/or <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> in the islet cell neoplasms.</p></div></div><div id="tuberous-sclerosis.Phenotype_Correlation"><h3>Phenotype Correlations by Gene</h3><p><i>TSC2</i> pathogenic variants produce a more severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than <i>TSC1</i> pathogenic variants. A higher percentage of individuals with more severe features of TSC have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> versus a <i>de novo TSC1</i> pathogenic variant [<a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al 2007</a>]. Individuals representing <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) are more likely to have a <i>TSC2</i> pathogenic variant, while those with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> TSC have an almost equal proportion of <i>TSC1</i> and <i>TSC2</i> pathogenic variants [<a class="bk_pop" href="#tuberous-sclerosis.REF.au.2007.88">Au et al 2007</a>].</p><p>Individuals with a <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at greater risk for:</p><ul><li class="half_rhythm"><div>Renal malignancy [<a class="bk_pop" href="#tuberous-sclerosis.REF.yang.2014.895">Yang et al 2014</a>]</div></li><li class="half_rhythm"><div>Intellectual disability[<a class="bk_pop" href="#tuberous-sclerosis.REF.kothare.2014.1025">Kothare et al 2014</a>]</div></li><li class="half_rhythm"><div>Autistic disorder, low IQ, and infantile spasms [<a class="bk_pop" href="#tuberous-sclerosis.REF.numis.2011.981">Numis et al 2011</a>]</div></li></ul></div><div id="tuberous-sclerosis.GenotypePhenotype_Cor"><h3>Genotype-Phenotype Correlations</h3><p><b><i>TSC2</i></b></p><ul><li class="half_rhythm"><div>Females with pathogenic variants on the carboxy terminus of tuberin, the <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>, may have increased incidence and/or severity of lymphangioleiomyomatosis [<a class="bk_pop" href="#tuberous-sclerosis.REF.strizheva.2001.253">Strizheva et al 2001</a>].</div></li><li class="half_rhythm"><div>Some pathogenic <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants &#x02013; including but not limited to p.Arg622Trp, p.Arg905Gln, p.Ser1036Pro, p.Arg1200Trp, p.Gln1503Pro, p.Gly1579Ser, and p.Arg1713His (see <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.tsc2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTtsc2pathogenicvar" rid-ob="figobtuberoussclerosisTtsc2pathogenicvar">Table 6</a>) &#x02013; are associated with milder disease phenotypes [<a class="bk_pop" href="#tuberous-sclerosis.REF.khare.2001.347">Khare et al 2001</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.oconnor.2003.409">O'Connor et al 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.mayer.2004.e64">Mayer et al 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.jansen.2006.528">Jansen et al 2006</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.wentink.2012.453">Wentink et al 2012</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.farach.2017.771">Farach et al 2017</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.fox.2017.744">Fox et al 2017</a>]. Many of the variants associated with a milder disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been identified in individuals with a family history of TSC.</div></li><li class="half_rhythm"><div>Renal cystic disease may be more severe in individuals with small <i>TSC2</i> pathogenic variants (single- to few-<a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> insertions, deletions, and single-nucleotide variants).</div></li></ul></div><div id="tuberous-sclerosis.Penetrance"><h3>Penetrance</h3><p>After detailed evaluation of each individual known to have a <i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of TSC is now thought to be 100%. Rare instances of apparent non-penetrance have been reported; however, molecular studies revealed the presence of two different pathogenic variants in the family and the existence of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in others [<a class="bk_pop" href="#tuberous-sclerosis.REF.connor.1986.1275">Connor et al 1986</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.webb.1991.417">Webb &#x00026; Osborne 1991</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.rose.1999.986">Rose et al 1999</a>].</p></div><div id="tuberous-sclerosis.Nomenclature"><h3>Nomenclature</h3><p>Terms used in the past to describe findings in tuberous sclerosis that are now outdated or inappropriate but have not yet been eliminated from the medical literature include the following:</p><ul><li class="half_rhythm"><div><b>Adenoma sebaceum.</b> Used previously to describe facial lesions that are now better characterized as facial angiofibromas because the lesions have no "sebaceous" elements</div></li><li class="half_rhythm"><div><b>Myomata.</b> Replaced by the more precise terms cardiac rhabdomyomas and cortical tubers</div></li><li class="half_rhythm"><div><b>White ash leaf spots.</b> Used previously to describe the hypopigmented macules; now discouraged because the hypopigmented macules can be any shape or size. Hypopigmented macules of a certain size and shape are not more or less indicative of an association with tuberous sclerosis complex.</div></li><li class="half_rhythm"><div><b>Epiloia.</b> Used to describe individuals with TSC and epilepsy</div></li></ul></div><div id="tuberous-sclerosis.Prevalence"><h3>Prevalence</h3><p>The incidence of TSC may be as high as 1:5,800 live births [<a class="bk_pop" href="#tuberous-sclerosis.REF.osborne.1991.125">Osborne et al 1991</a>]. A high mutation rate (1:250,000 per <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> per generation) is estimated [<a class="bk_pop" href="#tuberous-sclerosis.REF.sampson.1989.28">Sampson et al 1989</a>].</p></div></div><div id="tuberous-sclerosis.Genetically_Related_A"><h2 id="_tuberous-sclerosis_Genetically_Related_A_">Genetically Related (Allelic) Disorders</h2><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion-syndrome/">contiguous gene deletion syndrome</a></b> in which <i>PKD1</i> and the adjacent <i>TSC2</i> are disrupted by deletion has been described [<a class="bk_pop" href="#tuberous-sclerosis.REF.consugar.2008.1468">Consugar et al 2008</a>]. In individuals with this syndrome, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of tuberous sclerosis and severe polycystic kidney disease is usually evident in utero or is diagnosed in infancy.</p><p><b>Sporadic tumors</b> (including pulmonary lymphangioleiomyomatosis, perivascular epithelioid cell tumors, urothelial carcinomas, and hepatocellular carcinomas) occurring as single tumors in the absence of any other findings of TSC harbor somatic variants in <i>TSC1</i> or <i>TSC</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; thus, predisposition to these tumors is not heritable. For more details see <a href="#tuberous-sclerosis.Cancer_and_Benign_Tum">Cancer and Benign Tumors</a>.</p></div><div id="tuberous-sclerosis.Differential_Diagnosi"><h2 id="_tuberous-sclerosis_Differential_Diagnosi_">Differential Diagnosis</h2><p>Many of the features of TSC are nonspecific and can be seen as <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> findings or as a feature of another condition.</p><div id="tuberous-sclerosis.Skin_1"><h3>Skin</h3><p><b>Hypopigmented macules</b> have been observed in 0.8% of newborns in some studies and in most cases have no medical significance [<a class="bk_pop" href="#tuberous-sclerosis.REF.alper.1983.58">Alper &#x00026; Holmes 1983</a>]. A study by <a class="bk_pop" href="#tuberous-sclerosis.REF.vanderhooft.1996.355">Vanderhooft et al [1996]</a> determined that three or more hypopigmented macules are much more likely to be seen in an individual who will be diagnosed with TSC. Other conditions with hypopigmented macules as part of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> include vitiligo, nevus depigmentus, nevus anemicus, piebaldism, and Vogt-Koyanagi-Harada syndrome. Associated findings can usually distinguish these conditions from TSC.</p><p><b>Angiofibromas.</b> A single facial angiofibroma or even two is not diagnostic of TSC (see <a href="#tuberous-sclerosis.Suggestive_Findings">Suggestive Findings</a>). On physical examination, acne vulgaris, acne rosacea, or multiple trichoepithelioma can be mistaken for angiofibromas, but biopsy easily distinguishes among them.</p><p>The <b>shagreen patch</b> of TSC is quite specific based on location and appearance and was retained as a major diagnostic criteria for TSC. However, the diagnostic criteria has been updated to omit use of the term "connective tissue nevus" because this term encompasses a variety of skin lesions with excessive dermal connective tissue that are not necessarily associated with TSC.</p><p><b>Ungual fibromas</b> can result from trauma, but generally traumatic ungual fibromas are single lesions and their presence can be explained (e.g., by a particular manner of holding a golf club). Two or more ungual fibromas are now required as a major clinical diagnostic criterion for TSC. Ungual fibromas must be distinguished from epithelial inclusion cysts, verruca vulgaris, and infantile digital fibromatosis.</p></div><div id="tuberous-sclerosis.Kidneys_1"><h3>Kidneys</h3><p><b>Renal cysts</b> are seen commonly in the population (1%-2%), but uncommonly in individuals younger than age 30 years [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.1993.41">Northrup et al 1993</a>].</p><p><b>Renal angiomyolipomas (AMLs)</b> are rare tumors sometimes observed in individuals with no other medical problems. Studies have shown that such <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AMLs can have <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> for <i>TSC2</i>, leading to the conclusion that they occur as a result of loss of function of <i>TSC2</i> in individuals not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with tuberous sclerosis complex.</p></div><div id="tuberous-sclerosis.Lungs"><h3>Lungs</h3><p>Some women who have lymphangioleiomyomatosis (LAM) also have renal angiomyolipomas but no other findings of TSC. These individuals do not transmit TSC or LAM to their offspring. Individuals with LAM and renal angiomyolipomas who have no other features of TSC do not meet diagnostic criteria for TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>].</p></div><div id="tuberous-sclerosis.Heart_1"><h3>Heart</h3><p>Infants with cardiac rhabdomyomas have a 75%-80% chance of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with TSC. While cardiac rhabdomyomas can be observed as an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> finding, this is unusual. Potentially, sporadically occurring cardiac rhabdomyomas could also have a mechanism similar to the <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> AMLs described (see <a href="#tuberous-sclerosis.Kidneys_1">Kidneys</a>).</p></div></div><div id="tuberous-sclerosis.Management"><h2 id="_tuberous-sclerosis_Management_">Management</h2><p>Consensus clinical management and surveillance recommendations for individuals with TSC have been published [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.a">Krueger et al 2013a</a>] (<a href="/pmc/articles/PMC4058297" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="tuberous-sclerosis.Evaluations_Following"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with tuberous sclerosis complex (TSC), the evaluations summarized in <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.recommended_evaluat/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTrecommendedevaluat" rid-ob="figobtuberoussclerosisTrecommendedevaluat">Table 2</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended by the International Tuberous Sclerosis Consensus Conference [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>] (<a href="/pmc/articles/PMC4080684/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="tuberous-sclerosis.T.recommended_evaluat" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with TSC</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.T.recommended_evaluat/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.T.recommended_evaluat_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th></tr></thead><tbody><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Integument</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Detailed dermatologic &#x00026; dental exam</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blood pressure</div></li><li class="half_rhythm"><div>Renal function; obtain a serum creatinine level to determine GFR</div></li><li class="half_rhythm"><div>MRI of abdomen to assess for angiomyolipoma &#x00026; renal cysts</div></li></ul>
</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Central nervous system</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Brain MRI for tubers, SENs, migrational defects, SEGAs</div></li><li class="half_rhythm"><div>Evaluation for TAND</div></li><li class="half_rhythm"><div>EEG; if abnormal or if TAND is present: 24-hr video EEG to assess for subclinical seizure activity</div></li><li class="half_rhythm"><div>During infancy, educate parents to recognize infantile spasms even if none have occurred at time of 1st diagnosis.</div></li></ul>
</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmology</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete ophthalmologic evaluation, incl dilated fundoscopy to assess for retinal lesions &#x00026; visual field defects</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiology</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Echocardiogram in pediatric age group (esp if age &#x0003c;3 yrs)</div></li><li class="half_rhythm"><div>ECG in all ages to assess for underlying conduction defects</div></li></ul>
</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pulmonary</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Baseline pulmonary function testing (pulmonary function testing &#x00026; 6-min walk test) &#x00026; high-resolution chest computed tomography, even if asymptomatic, in individuals at risk for LAM (typically females age &#x02265;18 yrs)</div></li><li class="half_rhythm"><div>Adult males, if symptomatic, should also undergo pulmonary function testing.</div></li></ul>
</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_tuberous-sclerosis.T.recommended_evaluat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist and/or genetic counselor</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">GFR = glomerular filtration rate; SEGAs = subependymal giant cell astrocytomas ; SENs = subependymal nodules; TAND = TSC-associated neuropsychiatric disorder</p></div></dd></dl></div></div></div></div><div id="tuberous-sclerosis.Treatment_of_Manifest"><h3>Treatment of Manifestations</h3><p><b>Subependymal giant cell astrocytomas (SEGAs).</b> Early identification of an enlarging giant cell astrocytoma permits medical therapy with mTOR inhibitors [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.2010.1801">Krueger et al 2010</a>], which may obviate the need for neurosurgical intervention in many individuals. However, neurosurgery may still be indicated when the size of the SEGA causes life-threatening neurologic symptoms.</p><p><b>Seizures.</b> Early control of seizures is thought to prevent subsequent epileptic encephalopathy and reduce cognitive behavioral consequences [<a class="bk_pop" href="#tuberous-sclerosis.REF.bombardieri.2010.146">Bombardieri et al 2010</a>]. The efficacy of different treatments for infantile spasms varies among individuals; however a retrospective review found that vigabatrin controlled infantile spasms in 73% of children with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.camposano.2008.1186">Camposano et al 2008</a>] (see <a href="#tuberous-sclerosis.Prevention_of_Seconda">Prevention of Secondary Complications</a>). An ongoing study (see <a href="https://clinicaltrials.gov/ct2/show/NCT02849457" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">clinicaltrials.gov</a>) is prospectively investigating the effect of early vigabatrin treatment on developmental outcomes in babies with TSC-associated infantile spasms.</p><p>The seizures in TSC may be resistant to polydrug therapy with anticonvulsants. A number of small studies have reported excellent results after epilepsy surgery.</p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#tuberous-sclerosis.REF.jarrar.2004.479">Jarrar et al [2004]</a> found that unifocal-onset seizures and mild to no developmental delay at the time of surgery predict an excellent long-term outcome.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#tuberous-sclerosis.REF.romanelli.2004.239">Romanelli et al [2004]</a> discussed the use of electroencephalographic techniques, functional neuroimaging, and invasive cortical mapping to aid the surgeon in evaluating options for surgical resection in individuals with TSC who have multifocal epileptogenic zones.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#tuberous-sclerosis.REF.kagawa.2005.429">Kagawa et al [2005]</a> found that increased radiolabeled alpha-methyl-L-tryptophan uptake on PET scans identifies epileptogenic tubers with 83% accuracy, thus enhancing successful epilepsy surgery.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#tuberous-sclerosis.REF.weiner.2006.1494">Weiner et al [2006]</a> used a three-staged bilateral surgical approach in 22 persons with TSC. They suggest that this approach can help identify both primary and secondary epileptogenic zones in young persons with multiple tubers.</div></li></ul><p>Initial case reports suggested a potential for mTOR inhibitors to help in the treatment of intractable epilepsy in individuals with TSC [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.2013b.679">Krueger et al 2013b</a>]. The EXIST-3 clinical trial [<a class="bk_pop" href="#tuberous-sclerosis.REF.french.2016.2153">French et al 2016</a>] confirmed the benefit of these therapies; EXIST-3 received FDA approval (4/10/18) as adjunctive treatment of TSC-associated partial-onset seizures.</p><p><b>Renal angiomyolipoma</b></p><ul><li class="half_rhythm"><div>For asymptomatic, growing angiomyolipoma measuring &#x0003e;4 cm in diameter or &#x0003e;3 cm and growing rapidly, treatment with an mTOR inhibitor is currently recommended as the most effective first-line therapy in the short term [<a class="bk_pop" href="#tuberous-sclerosis.REF.davies.2011.4071">Davies et al 2011</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.bissler.2013.817">Bissler et al 2013</a>]. The demonstrated tolerability to date is far preferable to the renal damage caused by angiomyolipoma progression or surgical and embolitic/ablative therapies, though studies are still needed to confirm long-term benefits and safety [<a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.2013b.679">Krueger et al 2013b</a>].</div></li><li class="half_rhythm"><div>Selective embolization followed by corticosteroids, kidney-sparing resection, or ablative therapy for exophytic lesions is acceptable second-line therapy for asymptomatic angiomyolipomas [<a class="bk_pop" href="#tuberous-sclerosis.REF.bissler.2002.966">Bissler et al 2002</a>].</div></li><li class="half_rhythm"><div>For acute hemorrhage, embolization followed by corticosteroids is more appropriate [<a class="bk_pop" href="#tuberous-sclerosis.REF.mourikis.1999.153">Mourikis et al 1999</a>]. Nephrectomy is to be avoided because of the high incidence of complications and increased risk for future renal insufficiency and end-stage renal failure, and the poor prognosis that results from chronic kidney disease.</div></li></ul><p><b>Facial angiofibromas.</b> Topical mTOR inhibitor formulations have been shown to be efficacious in the treatment of facial angiofibromas.</p><p><b>Cardiac rhabdomyomas.</b> Previous standard of care for the treatment of newborns with cardiac rhabdomyomas resulting in life-threatening complications (i.e., outflow tract obstruction) was surgery. There have now been several reports of off-label use of mTOR inhibitors to treat cardiac rhabdomyomas in infants with TSC with encouraging results [<a class="bk_pop" href="#tuberous-sclerosis.REF.dogan.2015">Dogan et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.goyer.2015.450">Goyer et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.mlczoch.2015.618">Mlczoch et al 2015</a>]. These reports indicate that mTOR inhibitors may be a better alternative than surgery for clinically significant cardiac rhabdomyomas.</p><p><b>LAM.</b> Trials have demonstrated efficacy of mTOR inhibitors for LAM [<a class="bk_pop" href="#tuberous-sclerosis.REF.mccormack.2011.1595">McCormack et al 2011</a>]. The FDA approved use of mTOR inhibitors for treatment of the lung issues in people with TSC (5/28/15). Official guidelines for diagnosis and management of LAM have been published [<a class="bk_pop" href="#tuberous-sclerosis.REF.mccormack.2016">McCormack et al 2016</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.gupta.2017.1337">Gupta et al 2017</a>].</p></div><div id="tuberous-sclerosis.Prevention_of_Seconda"><h3>Prevention of Secondary Complications</h3><p><b>For those on vigabatrin therapy,</b> vision testing is recommended within four weeks of treatment initiation, every three months during therapy, and three to six months after treatment is discontinued because of the risk for peripheral visual field restriction (<a href="http://www.lundbeck.com/upload/us/files/pdf/Products/sabril_PI_US_EN.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SABRIL prescribing information</a>).</p></div><div id="tuberous-sclerosis.Surveillance"><h3>Surveillance</h3><p>The following routine monitoring is recommended for individuals with TSC (adapted from <a class="bk_pop" href="#tuberous-sclerosis.REF.krueger.a">Krueger et al [2013a]</a>, <a href="/pmc/articles/PMC4058297/table/T3/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Table 3</a>).</p><p><b>Central nervous system</b></p><ul><li class="half_rhythm"><div>Obtain MRI of the brain every one to three years in asymptomatic (i.e., having no CNS-related symptoms) individuals with TSC younger than age 25 years to monitor for new occurrence of SEGA. Those with asymptomatic SEGA in childhood should continue to be imaged periodically as adults to ensure that there is no growth.</div></li><li class="half_rhythm"><div>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with large or growing SEGA causing ventricular enlargement who are still asymptomatic, brain MRI scans should be performed more frequently and these individuals and their families should be educated regarding the potential for new symptoms.</div></li><li class="half_rhythm"><div>Perform screening for TAND features at least annually. Perform comprehensive formal evaluation for TAND at key developmental points: infancy (0-3 years), preschool (3-6 years), pre-middle school (6-9 years), adolescence (12-16 years), early adulthood (18-25 years), and as needed thereafter.</div></li><li class="half_rhythm"><div>Obtain routine EEG in individuals with known or suspected seizure activity. The frequency of routine EEG should be determined by clinical need.</div></li></ul><p><b>Renal</b></p><ul><li class="half_rhythm"><div>Obtain MRI of the abdomen to assess for progression of angiomyolipomas and renal cystic disease every one to three years throughout the lifetime of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual.</div></li><li class="half_rhythm"><div>Assess renal function (including determination of GFR) and blood pressure at least annually.</div></li></ul><p><b>Cardiac</b></p><ul><li class="half_rhythm"><div>In asymptomatic infants and children with documented cardiac rhabdomyomas, obtain an echocardiogram every one to three years until regression of the cardiac rhabdomyomas is documented.</div></li><li class="half_rhythm"><div>More frequent or advanced diagnostic assessment may be required for symptomatic individuals.</div></li></ul><p><b>Pulmonary</b></p><ul><li class="half_rhythm"><div>Perform clinical screening (targeted history) for LAM symptoms including exertional dyspnea and shortness of breath at each clinic visit for women older than age 18 years or those who report respiratory symptoms. Counseling regarding smoking risk and estrogen use should be reviewed at each clinic visit for individuals at risk for LAM.</div></li><li class="half_rhythm"><div>Obtain a high-resolution computed tomography (HCRT) of the lungs every five to ten years in asymptomatic individuals at risk for LAM who have no evidence of lung cysts on baseline HRCT. Individuals with lung cysts detected on HRCT should have annual pulmonary function testing (pulmonary function test and 6-minute walk) and HRCT every two to three years.</div></li></ul><p><b>Skin.</b> Perform detailed clinical dermatologic inspection/exam annually.</p><p><b>Dental.</b> Perform detailed clinical dental inspection/exam at minimum every six months and panoramic radiographs by age seven years, if not performed previously.</p><p><b>Ophthalmologic.</b> Perform annual ophthalmologic evaluation in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with previously identified ophthalmologic lesions or vision symptoms at the baseline evaluation.</p></div><div id="tuberous-sclerosis.AgentsCircumstances_t"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Smoking</div></li><li class="half_rhythm"><div>Estrogen use in adolescent and adult females</div></li><li class="half_rhythm"><div>Nephrectomy (see <a href="#tuberous-sclerosis.Treatment_of_Manifest">Treatment of Manifestations</a>, <b>Renal angiomyolipoma</b>)</div></li></ul></div><div id="tuberous-sclerosis.Evaluation_of_Relativ"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from surveillance and early treatment. Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, physical examination and imaging studies (skin examination, retinal examination, brain imaging, and renal ultrasound examination) to assess for the clinical features of TSC (see <a href="#tuberous-sclerosis.Diagnosis">Diagnosis</a>).</div></li></ul><p>See <a href="#tuberous-sclerosis.Related_Genetic_Couns">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="tuberous-sclerosis.Pregnancy_Management"><h3>Pregnancy Management</h3><p>In general, women with epilepsy or a seizure disorder from any cause are at greater risk for mortality during pregnancy than pregnant women without a seizure disorder; use of antiepileptic medication during pregnancy reduces this risk. However, exposure to antiepileptic medication may increase the risk for adverse fetal outcome (depending on the drug used, the dose, and the stage of pregnancy at which medication is taken). Nevertheless, the risk of an adverse outcome to the fetus from antiepileptic medication exposure is often less than that associated with exposure to an untreated maternal seizure disorder. Therefore, use of antiepileptic medication to treat a maternal seizure disorder during pregnancy is typically recommended. Discussion of the risks and benefits of using a given antiepileptic drug during pregnancy should ideally take place prior to conception. Transitioning to a lower-risk medication prior to pregnancy may be possible [<a class="bk_pop" href="#tuberous-sclerosis.REF.sarma.2016.467">Sarma et al 2016</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for more information on medication use during pregnancy.</p></div><div id="tuberous-sclerosis.Therapies_Under_Inves"><h3>Therapies Under Investigation</h3><p>Many clinical trials are assessing the effect of drug therapy on the manifestations of TSC (see <a href="http://clinicaltrials.gov/ct2/results?term=tuberous+sclerosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>).</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="tuberous-sclerosis.Genetic_Counseling"><h2 id="_tuberous-sclerosis_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="tuberous-sclerosis.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Tuberous sclerosis complex (TSC) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="tuberous-sclerosis.Risk_to_Family_Member"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>About one third of individuals diagnosed with TSC have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>Two thirds of individuals with TSC have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Recommendations for the clinical and genetic evaluation of parents of a child with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include the following:</div><ul><li class="half_rhythm"><div>Targeted <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the child</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified in the child, skin examination, retinal examination, brain imaging, and renal ultrasound examination of the parents to determine their clinical status</div></li></ul></li><li class="half_rhythm"><div>Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of a milder phenotypic presentation.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Germline mosaicism studies are typically limited to families with two or more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children and unaffected parents. Of 120 such families, <a class="bk_pop" href="#tuberous-sclerosis.REF.rose.1999.986">Rose et al [1999]</a> identified six (5%) with molecularly confirmed germline mosaicism. Of these, one pathogenic variant was in <i>TSC1</i> and five in <i>TSC2;</i> pathogenic variants included <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and a one-nucleotide <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> or <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with TSC may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the recognition of symptoms, or late onset of the disorder in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the known <i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent or the parents have not been tested for the pathogenic variant but are clinically unaffected, the risk to sibs of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> is low (~1%-2%) but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with tuberous sclerosis has a 50% chance of inheriting the <i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="tuberous-sclerosis.Related_Genetic_Couns"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#tuberous-sclerosis.Evaluation_of_Relativ">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Predictive testing</b> for at-risk asymptomatic adult family members requires prior identification of the <i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Considerations in families with apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with TSC has the pathogenic variant or clinical evidence of the disorder, the <i>TSC1</i> or <i>TSC2</i> pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="tuberous-sclerosis.Prenatal_Testing_and"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancies</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Molecular genetic testing.</b> Once the <i>TSC1</i> or <i>TSC2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for TSC are possible.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Fetal imaging studies.</b> For families in which a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified, high-resolution ultrasound examination for tumors is possible; however, its <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> is unknown. Fetal MRI may be of use in the evaluation of TSC in fetuses at 50% risk.</div><div class="half_rhythm">Note: The cardiac tumors are generally not detected until the third trimester.</div></li></ul><p><b>Low-risk pregnancies.</b> When cardiac lesions consistent with rhabdomyoma are identified on fetal ultrasound examination, the risk to the fetus with no known family history of TSC of having TSC is 75%-80% [<a class="bk_pop" href="#tuberous-sclerosis.REF.northrup.2013">Northrup et al 2013</a>].</p></div></div><div id="tuberous-sclerosis.Resources"><h2 id="_tuberous-sclerosis_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/tuberoussclerosis.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberous Sclerosis</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/tuberous-sclerosis-complex" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberous sclerosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22245/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberous sclerosis</a></div></li><li class="half_rhythm"><div><b>Tuberous Sclerosis Alliance</b></div><div>801 Roeder Road</div><div>Suite 750</div><div>Silver Spring MD 20910</div><div><b>Phone:</b> 800-225-6872 (toll-free); 301-562-9890</div><div><b>Fax:</b> 301-562-9870</div><div><b>Email:</b> info@tsalliance.org</div><div><a href="http://www.tsalliance.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.tsalliance.org</a></div></li><li class="half_rhythm"><div><b>American Epilepsy Society (AES)</b></div><div><a href="http://www.aesnet.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aesnet.org</a></div></li><li class="half_rhythm"><div><b>Epilepsy Foundation</b></div><div>8301 Professional Place East</div><div>Suite 200</div><div>Landover MD 20785-7223</div><div><b>Phone:</b> 800-332-1000 (toll-free)</div><div><b>Email:</b> ContactUs@efa.org</div><div><a href="https://www.epilepsy.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.epilepsy.com</a></div></li><li class="half_rhythm"><div><b>The LAM Foundation</b></div><div>4015 Executive Park Dr</div><div>Suite 320</div><div>Cincinnati OH 45241</div><div><b>Phone:</b> 513-777-6889; 877-CURELAM (877-287-3526)</div><div><b>Email:</b> info@thelamfoundation.org</div><div><a href="http://www.thelamfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">The LAM Foundation</a></div></li></ul></div><div id="tuberous-sclerosis.Molecular_Genetics"><h2 id="_tuberous-sclerosis_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="tuberous-sclerosis.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Tuberous Sclerosis Complex: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7248" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TSC1</i></a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7248" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">9q34<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92574" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hamartin</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/TSC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberous sclerosis database (TSC1)</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TSC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TSC1</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TSC1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TSC1</a></td></tr><tr><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7249" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TSC2</i></a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7249" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P49815" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberin</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/TSC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tuberous sclerosis database (TSC2)</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TSC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TSC2</a></td><td headers="hd_b_tuberous-sclerosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TSC2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TSC2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="tuberous-sclerosis.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="tuberous-sclerosis.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Tuberous Sclerosis Complex (<a href="/omim/191092,191100,605284,613254" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/191092" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">191092</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TSC2 GENE; TSC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/191100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">191100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TUBEROUS SCLEROSIS 1; TSC1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605284" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605284</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TSC1 GENE; TSC1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613254" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613254</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TUBEROUS SCLEROSIS 2; TSC2</td></tr></tbody></table></div></div><div id="tuberous-sclerosis.Molecular_Pathogenesi"><h3>Molecular Pathogenesis</h3><p>Hamartin and tuberin form heterodimers, suggesting that they act in concert to regulate cell growth and proliferation [<a class="bk_pop" href="#tuberous-sclerosis.REF.plank.1998.4766">Plank et al 1998</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.van_slegtenhorst.1998.1053">van Slegtenhorst et al 1998</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.han.2011.973">Han &#x00026; Sahin 2011</a>]. Tuberin and hamartin were shown to be key regulators of the AKT/mTOR signaling pathway and to participate in several other signaling pathways including the MAPK, AMPK, b-catenin, calmodulin, CDK, autophagy, and cell cycle pathways [<a class="bk_pop" href="#tuberous-sclerosis.REF.kozma.2002.65">Kozma &#x00026; Thomas 2002</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.astrinidis.2003.51372">Astrinidis et al 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.elhashemite.2003.1348">El-Hashemite et al 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.harris.2003.re15">Harris &#x00026; Lawrence 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.yeung.2003.368">Yeung 2003</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.au.2004.699">Au et al 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.birchenallroberts.2004.25605">Birchenall-Roberts et al 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.li.2004.32">Li et al 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.mak.2004.588">Mak &#x00026; Yeung 2004</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.zhang.2013.1186">Zhang et al 2013</a>]. The hamartin tuberin complex can also regulate mTORC2 complex activity that affects cytoskeleton formation and AKT activation [<a class="bk_pop" href="#tuberous-sclerosis.REF.han.2011.973">Han &#x00026; Sahin 2011</a>]. These observations are consistent with more signaling pathway kinases targeting tuberin than hamartin to destabilize the tuberin-hamartin complex, thereby releasing suppression of mTOR functions allowing protein translation, cell growth, and proliferation.</p><p>Most <i>TSC1</i> pathogenic variants and 70% of <i>TSC2</i> pathogenic variants are predicted to result in a loss of functional protein products. Subsequent loss of function leads to uncontrolled cell growth and cell proliferation resulting in the formation of hamartias (a focal malformation consisting of disorganized arrangement of tissue types that are normally present in the anatomic area) and hamartomas [<a class="bk_pop" href="#tuberous-sclerosis.REF.au.2004.699">Au et al 2004</a>].</p><p>Additionally, because tuberin and hamartin are subjected to multiple cell signaling pathway regulation, the quantity and quality of both somatic pathogenic variants and environmental factors targeting these pathways are expected to modify disease expression in individuals who have only one normal <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> copy of <i>TSC1</i> or <i>TSC2</i>.</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is defined as a variant that clearly inactivates the function of the TSC1 or TSC2 proteins (i.e., out-of-frame <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant), prevents protein synthesis (i.e., large <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>), or is a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant whose effect on protein function has been established by functional assessment (see <a href="http://chromium.lovd.nl/LOVD2/TSC/home.php?select_db=TSC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD Database &#x02013; TSC1</a>, <a href="http://chromium.lovd.nl/LOVD2/TSC/home.php?select_db=TSC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD Database &#x02013; TSC2</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.hoogeveenwesterveld.2012.476">Hoogeveen-Westerveld et al [2012]</a>, and <a class="bk_pop" href="#tuberous-sclerosis.REF.hoogeveenwesterveld.2013.167">Hoogeveen-Westerveld et al [2013]</a>). Other <i>TSC1</i> or <i>TSC2</i> variants whose effects on function are less certain do not meet the criteria for diagnosis of TSC.</p><div id="tuberous-sclerosis.TSC1"><h4><i>TSC1</i></h4><p><b>Gene structure.</b>
<i>TSC1</i> is approximately 50 kb in size and the longest transcript variant (<a href="/nuccore/NM_000368.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000368.4</a>), comprising 23 exons. The first two exons are noncoding. Exon 5 and <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 12 are alternatively spliced, producing shorter transcript variants. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Almost all <i>TSC1</i> pathogenic variants are predicted to cause truncation of the hamartin protein; the location of the <i>TSC1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> does not appear to associate with disease severity. Approximately 650 unique <i>TSC1</i> pathogenic variants have been identified in more than 1,950 individuals/families with <i>TSC1</i>-related TSC (<a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>). Most pathogenic variants are unique, but a few are known to recur, including those in specific codons of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15. Other pathogenic variants are scattered throughout the exons and splice sites. A small percentage of pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have been identified and located mostly in the region encoding the N-terminal of hamartin [<a class="bk_pop" href="#tuberous-sclerosis.REF.choi.2006.440">Choi et al 2006</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.lee.2007.440">Lee et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.mozaffari.2009.88">Mozaffari et al 2009</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.nellist.2009.319">Nellist et al 2009</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.hoogeveenwesterveld.2012.476">Hoogeveen-Westerveld et al 2012</a>].</p><p>Pathogenic variant types by percentage are shown in <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.types_of_pathogenic/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTtypesofpathogenic" rid-ob="figobtuberoussclerosisTtypesofpathogenic">Table 4</a>.</p><div id="tuberous-sclerosis.T.types_of_pathogenic" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Types of Pathogenic Variants Observed in <i>TSC1</i> (n=651)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.T.types_of_pathogenic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.T.types_of_pathogenic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th id="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Percent of All <i>TSC1</i> Pathogenic Variants&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Small deletions and insertions</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">57.8%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nonsense</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.7%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splice</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.9%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Large deletions and rearrangements</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.9%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense&#x000a0;<sup>2</sup></td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.7%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tuberous-sclerosis.TF.4.1"><p class="no_margin">Estimated percentages from <a href="http://chromium.lovd.nl/LOVD2/TSC/home.php?select_db=TSC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD</a></p></div></dd><dt>2. </dt><dd><div id="tuberous-sclerosis.TF.4.2"><p class="no_margin">A small percentage of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have been identified in <i>TSC1</i> with demonstrated functional loss by in vitro assays [<a class="bk_pop" href="#tuberous-sclerosis.REF.choi.2006.440">Choi et al 2006</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.lee.2007.440">Lee et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.mozaffari.2009.88">Mozaffari et al 2009</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.nellist.2009.319">Nellist et al 2009</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.hoogeveenwesterveld.2012.476">Hoogeveen-Westerveld et al 2012</a>].</p></div></dd></dl></div></div></div><p>For more information, see <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene has no known structural homologies to other known gene families.</p><p>The protein product, hamartin, has one transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and two coiled-coil domains. The first coiled-coil domain is necessary for protein-protein interactions between hamartin and tuberin. A second coiled-coil domain peptide, encoded by exons 17 to 23, interacts with tuberin to stabilize the tuberin-hamartin complex. Other domains are responsible for interacting with cytoskeletal ERM proteins, small G-protein Rho, cell division protein kinases, and I kappa kinase &#x003b2; (IKK-&#x003b2;). A study of the crystal structures of hamartin has mapped most of the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants to the inside of the folded hamartin N-terminal globular structure and suggested that these variants may destabilize the globular structure of hamartin, leading to dissociation of the tuberin-hamartin complex [<a class="bk_pop" href="#tuberous-sclerosis.REF.sun.2013.2135">Sun et al 2013</a>].</p><p>A major function of hamartin is to stabilize the hamartin tuberin complex to facilitate the GTPase-activating function of tuberin in the complex [<a class="bk_pop" href="#tuberous-sclerosis.REF.han.2011.973">Han &#x00026; Sahin 2011</a>]. In addition, hamartin interacts with the ezrin-radxin-moesin (ERM) family of actin-binding proteins [<a class="bk_pop" href="#tuberous-sclerosis.REF.lamb.2000.281">Lamb et al 2000</a>] and hamartin also regulates the cell cycle through interaction with CDK [<a class="bk_pop" href="#tuberous-sclerosis.REF.astrinidis.2003.51372">Astrinidis et al 2003</a>]. Growth of neurites, synapse formation, and axon development are also regulated by hamartin [<a class="bk_pop" href="#tuberous-sclerosis.REF.floricel.2007.502">Floricel et al 2007</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.knox.2007.e375">Knox et al 2007</a>]. Hamartin was suppressed by TNF&#x003b1;-activated IKK-&#x003b2; phosphorylation at amino acid residue Ser511 resulting in dissociation of tuberin hamartin complex, activating S6Kinase and VEGF production [<a class="bk_pop" href="#tuberous-sclerosis.REF.lee.2007.440">Lee et al 2007</a>]. A recent study demonstrated that hamartin can facilitate molecular chaperone heat-shock protein 90 (Hsp90) to mediate correct folding of tuberin and prevent tubulin from ubiquitination and proteasomal degradation [<a class="bk_pop" href="#tuberous-sclerosis.REF.woodford.2017.3650">Woodford et al 2017</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#tuberous-sclerosis.Molecular_Pathogenesi">Molecular Pathogenesis</a>.</p></div><div id="tuberous-sclerosis.TSC2"><h4><i>TSC2</i></h4><p><b>Gene structure.</b>
<i>TSC2</i> is approximately 50 kb in size; the longest transcript variant <a href="/nuccore/116256351" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000548.3</a> comprises 42 exons. A noncoding <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1a has recently been identified in addition to at least six alternatively spliced transcripts. Exons 25 and 31 are alternatively spliced. The 3&#x02032; ends of <i>TSC2</i> and <i>PKD1</i> overlap with three base pairs, explaining how <i>TSC2/PKD1</i> contiguous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> syndrome occurs when a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> spans both genes. For a detailed summary of gene and protein information, see <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 1,900 unique <i>TSC2</i> pathogenic variants distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been identified in more than 5,800 individuals/families with <i>TSC2</i>-related TSC. Approximately 33% of <i>TSC2</i> pathogenic variants are located in exons 32-41 (and associated splice sites) that encode the carboxy <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of tuberin consisting of several important functional motifs (e.g., GAP domain, estrogen receptor- and calmodulin-binding domains, and multiple signal pathway kinase targets).</p><p>Pathogenic variant types by percentage are shown in <a class="figpopup" href="/books/NBK1220/table/tuberous-sclerosis.T.types_of_pathogenic_1/?report=objectonly" target="object" rid-figpopup="figtuberoussclerosisTtypesofpathogenic1" rid-ob="figobtuberoussclerosisTtypesofpathogenic1">Table 5</a>.</p><p>Missense variants account for approximately 26% of all <i>TSC2</i> pathogenic variants with approximately 50% concentrated in the carboxy <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. Missense variants are rarely the direct target of kinases: only two <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants at the Tyr1571 residue are the predicted target of tyrosine kinase [<a class="bk_pop" href="#tuberous-sclerosis.REF.hoogeveenwesterveld.2013.167">Hoogeveen-Westerveld et al 2013</a>].</p><div id="tuberous-sclerosis.T.types_of_pathogenic_1" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Types of Pathogenic Variants Observed in <i>TSC2</i> (n=1947)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.T.types_of_pathogenic_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.T.types_of_pathogenic_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th id="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Percent of All <i>TSC2</i> Pathogenic Variants&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Small deletions and insertions</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~37.7%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~25.7%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nonsense</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~14.5%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splice</td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~16.6%</td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Large deletions and rearrangements&#x000a0;<sup>2</sup></td><td headers="hd_h_tuberous-sclerosis.T.types_of_pathogenic_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5.4%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tuberous-sclerosis.TF.5.1"><p class="no_margin">Estimated percentages from <a href="http://chromium.lovd.nl/LOVD2/TSC/home.php?select_db=TSC2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LOVD</a></p></div></dd><dt>2. </dt><dd><div id="tuberous-sclerosis.TF.5.2"><p class="no_margin">Approximately 5% of <i>TSC2</i> pathogenic variants are large deletions or rearrangements; 4.5% are partial-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions and 0.5% whole-gene deletions. Approximately half of all larger gene deletions involve both <i>TSC2</i> and <i>PKD1</i>.</p></div></dd></dl></div></div></div><p>For more information, see <a href="/books/NBK1220/#tuberous-sclerosis.molgen.TA">Table A</a>.</p><div id="tuberous-sclerosis.T.tsc2_pathogenic_var" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p><i>TSC2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1220/table/tuberous-sclerosis.T.tsc2_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tuberous-sclerosis.T.tsc2_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1864C&#x0003e;T</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg622Trp&#x000a0;<sup>1</sup></td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_3" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/116256351" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000548<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/116256352" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000539<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2714G&#x0003e;A</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg905Gln&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3106T&#x0003e;C</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser1036Pro&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3598C&#x0003e;T</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1200Trp&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4508A&#x0003e;C</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1503Pro&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4735G&#x0003e;A</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly1579Ser&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5138G&#x0003e;A</td><td headers="hd_h_tuberous-sclerosis.T.tsc2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1713His&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="tuberous-sclerosis.TF.6.1"><p class="no_margin">See <a href="#tuberous-sclerosis.GenotypePhenotype_Cor">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene product, tuberin, has GTPase-activating protein functions as a major regulator of small G-protein Rheb and the mTORC1 downstream signaling pathway on protein translation and cell growth and proliferation [<a class="bk_pop" href="#tuberous-sclerosis.REF.inoki.2003.1829">Inoki et al 2003</a>]. Tuberin also functions to regulate other small G-proteins such as Rap1a and Rab5 [<a class="bk_pop" href="#tuberous-sclerosis.REF.xiao.1997.6097">Xiao et al 1997</a>]. Activity of tuberin is suppressed by AKT and ERK2 and activated by GSK3 and AMPK [<a class="bk_pop" href="#tuberous-sclerosis.REF.han.2011.973">Han &#x00026; Sahin 2011</a>]. See <a href="#tuberous-sclerosis.Molecular_Pathogenesi">Molecular Pathogenesis</a>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#tuberous-sclerosis.Molecular_Pathogenesi">Molecular Pathogenesis</a>.</p></div></div><div id="tuberous-sclerosis.Cancer_and_Benign_Tum"><h3>Cancer and Benign Tumors</h3><p><b>Pulmonary lymphangioleiomyomatosis (LAM).</b> DNA extracted from lung tissue of some individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> LAM harbors pathogenic variants in <i>TSC2</i> or <i>TSC1</i> not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> [<a class="bk_pop" href="#tuberous-sclerosis.REF.smolarek.1998.810">Smolarek et al 1998</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.carsillo.2000.6085">Carsillo et al 2000</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.sato.2002.20">Sato et al 2002</a>]. Tuberin is strongly expressed in LAM tissues [<a class="bk_pop" href="#tuberous-sclerosis.REF.johnson.2002.458">Johnson et al 2002</a>]. A recent study demonstrated that not all the cells in sporadic LAM nodules contained pathogenic <i>TSC1</i> or <i>TSC2</i> variants; the range was 4%-60% [<a class="bk_pop" href="#tuberous-sclerosis.REF.badri.2013.663">Badri et al 2013</a>].</p><p><b>Perivascular epitheloid cell tumors (PEComa).</b> In some PEComa, reported loss of either <i>TSC2</i> or <i>TSC1</i> [<a class="bk_pop" href="#tuberous-sclerosis.REF.pan.2008.387">Pan et al 2008</a>] is evidence to support an oncogenic lineage of PEComa and angiomyolipomas in TSC. Six of 11 PEComas studied showed partial to complete responses to mTOR inhibitors [<a class="bk_pop" href="#tuberous-sclerosis.REF.dickson.2013.1711">Dickson et al 2013</a>].</p><p><b>Urothelial carcinomas.</b> A significant proportion of urothelial carcinomas were found to have a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> in <i>TSC1</i> and some had a somatic pathogenic variant in <i>TSC2</i> [<a class="bk_pop" href="#tuberous-sclerosis.REF.pymar.2008.2006">Pymar et al 2008</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.sj_dahl.2011.e18583">Sj&#x000f6;dahl et al 2011</a>]. These findings suggest that a significant proportion of urothelial carcinomas may respond to mTORC1 inhibitors.</p><p><b>Hepatocellular carcinomas.</b> Recent reports showed that approximately 10%-20% of hepatocellular carcinomas are associated with <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> somatic pathogenic variants in <i>TSC2</i> and suggested that these carcinomas may respond to mTORC1 inhibitors [<a class="bk_pop" href="#tuberous-sclerosis.REF.huynh.2015.1224">Huynh et al 2015</a>, <a class="bk_pop" href="#tuberous-sclerosis.REF.cho.2016.466">Cho et al 2016</a>].</p></div></div><div id="tuberous-sclerosis.References"><h2 id="_tuberous-sclerosis_References_">References</h2><div id="tuberous-sclerosis.Published_Guidelines"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.gupta.2017.1337">Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, Inoue Y, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX., ATS Assembly on Clinical Problems.  Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. an official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2017;<span class="ref-vol">196</span>:1337–48.</span> [<a href="/pmc/articles/PMC5694834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5694834</span></a>] [<a href="/pubmed/29140122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29140122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.krueger.2013">Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058297/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 5-28-19. [<a href="/pmc/articles/PMC4058297/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4058297</span></a>] [<a href="/pubmed/24053983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24053983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mccormack.2016">McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803656/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2016. Accessed 5-28-19. [<a href="/pmc/articles/PMC5803656/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5803656</span></a>] [<a href="/pubmed/27628078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27628078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.northrup.2013">Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058297/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 5-28-19.</div></li></ul></div><div id="tuberous-sclerosis.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.adriaensen.2011.625">Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. <span><span class="ref-journal">Clin Radiol. </span>2011;<span class="ref-vol">66</span>:625–8.</span> [<a href="/pubmed/21459371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21459371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.alper.1983.58">Alper JC, Holmes LB. The incidence and significance of birthmarks in a cohort of 4,641 newborns. <span><span class="ref-journal">Pediatr Dermatol. </span>1983;<span class="ref-vol">1</span>:58–68.</span> [<a href="/pubmed/6679890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6679890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.astrinidis.2003.51372">Astrinidis A, Senapedis W, Coleman TR, Henske EP. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:51372–9.</span> [<a href="/pubmed/14551205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14551205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.au.2004.699">Au KS, Williams AT, Gambello MJ, Northrup H. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. <span><span class="ref-journal">J Child Neurol. </span>2004;<span class="ref-vol">19</span>:699–709.</span> [<a href="/pubmed/15563017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15563017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.au.2007.88">Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. <span><span class="ref-journal">Genet Med. </span>2007;<span class="ref-vol">9</span>:88–100.</span> [<a href="/pubmed/17304050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17304050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.avila.2007.277">Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. <span><span class="ref-journal">Radiology. </span>2007;<span class="ref-vol">242</span>:277–85.</span> [<a href="/pmc/articles/PMC2940246/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2940246</span></a>] [<a href="/pubmed/17105849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17105849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.badri.2013.663">Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, Qin W, Chekaluk Y, Kwiatkowski DJ, Zhe X. Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2013;<span class="ref-vol">187</span>:663–5.</span> [<a href="/pmc/articles/PMC3733437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3733437</span></a>] [<a href="/pubmed/23504366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23504366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.birchenallroberts.2004.25605">Birchenall-Roberts MC, Fu T, Bang OS, Dambach M, Resau JH, Sadowski CL, Bertolette DC, Lee HJ, Kim SJ, Ruscetti FW. Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins. A molecular link of two tumor suppressor pathways. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:25605–13.</span> [<a href="/pubmed/15066998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15066998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.bissler.2013.817">Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>:817–24.</span> [<a href="/pubmed/23312829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23312829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.bissler.2002.966">Bissler JJ, Racadio J, Donnelly LF, Johnson ND. Reduction of post-embolization syndrome after ablation of renal angiomyolipoma. <span><span class="ref-journal">Am J Kidney Dis. </span>2002;<span class="ref-vol">39</span>:966–71.</span> [<a href="/pubmed/11979340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11979340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.bolton.2015.2321">Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Marechal K, Higgins JNP, Neville BGR, Rijsdjik F., The Tuberous Sclerosis 200 Study Group, Yates JRW.  Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. <span><span class="ref-journal">Psychol Med. </span>2015;<span class="ref-vol">45</span>:2321–31.</span> [<a href="/pubmed/25827976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25827976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.bolton.2002.1247">Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:1247–55.</span> [<a href="/pubmed/12023313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12023313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.bombardieri.2010.146">Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2010;<span class="ref-vol">14</span>:146–9.</span> [<a href="/pubmed/19369101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19369101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.borkowska.2011.13">Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. <span><span class="ref-journal">Int J Dermatol. </span>2011;<span class="ref-vol">50</span>:13–20.</span> [<a href="/pubmed/21182496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21182496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.camposano.2008.1186">Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. <span><span class="ref-journal">Epilepsia. </span>2008;<span class="ref-vol">49</span>:1186–91.</span> [<a href="/pubmed/18479386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18479386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.cancellieri.2002.263">Cancellieri A, Poletti V, Corrin B. Respiratory failure due ot micronodular type II pneumocyte hyperplasia. <span><span class="ref-journal">Histopathology. </span>2002;<span class="ref-vol">41</span>:263–5.</span> [<a href="/pubmed/12207789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12207789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.capal.2017.245">Capal J.K., Bernardino-Cuesta B., Horn P.S., Murray D., Byars A.W., Bing N.M., Kent B., Pearson D.A, Sahin M., Krueger D.A., TACERN Study Group.  Influence of seizures on early development in tuberous sclerosis complex. <span><span class="ref-journal">Epilepsy &#x00026; Behavior. </span>2017;<span class="ref-vol">70</span>:245–252.</span> [<a href="/pmc/articles/PMC5497719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5497719</span></a>] [<a href="/pubmed/28457992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28457992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.carsillo.2000.6085">Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2000;<span class="ref-vol">97</span>:6085–90.</span> [<a href="/pmc/articles/PMC18562/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC18562</span></a>] [<a href="/pubmed/10823953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10823953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.cho.2016.466">Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, Ha SY, Park CK, Lim HY. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. <span><span class="ref-journal">Transl Oncol. </span>2016;<span class="ref-vol">9</span>:466–71.</span> [<a href="/pmc/articles/PMC5067924/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5067924</span></a>] [<a href="/pubmed/27751352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27751352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.choi.2006.440">Choi JE, Chae JH, Hwang YS, Kim KJ. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex. <span><span class="ref-journal">Brain Dev. </span>2006;<span class="ref-vol">28</span>:440–6.</span> [<a href="/pubmed/16554133" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16554133</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.chung.2011.263">Chung TK, Lynch ER, Fiser CJ, Nelson DA, Agricola K, Tudor C, Franz DN, Krueger DA. Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex. <span><span class="ref-journal">Ann Clin Psychiatry. </span>2011;<span class="ref-vol">23</span>:263–9.</span> [<a href="/pubmed/22073383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22073383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.connor.1986.1275">Connor JM, Stephenson JB, Hadley MD. Non-penetrance in tuberous sclerosis. <span><span class="ref-journal">Lancet. </span>1986;<span class="ref-vol">2</span>:1275.</span> [<a href="/pubmed/2878149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2878149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.consugar.2008.1468">Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC. CRISP Consortium. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. <span><span class="ref-journal">Kidney Int. </span>2008;<span class="ref-vol">74</span>:1468–79.</span> [<a href="/pmc/articles/PMC2756756/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2756756</span></a>] [<a href="/pubmed/18818683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18818683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.crino.2006.1345">Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">355</span>:1345–56.</span> [<a href="/pubmed/17005952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17005952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.curatolo.2015.733">Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. <span><span class="ref-journal">Lancet Neurol. </span>2015;<span class="ref-vol">14</span>:733–45.</span> [<a href="/pubmed/26067126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26067126</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.dabora.2001.64">Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:64–80.</span> [<a href="/pmc/articles/PMC1234935/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1234935</span></a>] [<a href="/pubmed/11112665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11112665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.davies.2011.4071">Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR. Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial. <span><span class="ref-journal">Clin Cancer Res. </span>2011;<span class="ref-vol">17</span>:4071–81.</span> [<a href="/pubmed/21525172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21525172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.de_vries.a">de Vries PJ. Neurodevelopmental, psychiatric, and cognitive aspects of tuberous sclerosis complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, eds. <em>Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics</em>. Weinheim, Germany: Wiley-Blackwell; 2010a:229267.</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.de_vries.2010b.275">de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. <span><span class="ref-journal">Neurotherapeutics. </span>2010b;<span class="ref-vol">7</span>:275–82.</span> [<a href="/pmc/articles/PMC5084231/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5084231</span></a>] [<a href="/pubmed/20643380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20643380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.de_vries.2009.387">de Vries PJ, Gardiner J, Bolton PF. Neuropsychological attention deficits in tuberous sclerosis complex (TSC). <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:387–95.</span> [<a href="/pubmed/19215038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19215038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.de_vries.2007.16">de Vries PJ, Hunt A, Bolton PF. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. <span><span class="ref-journal">Eur Child Adolesc Psychiatry. </span>2007;<span class="ref-vol">16</span>:16–24.</span> [<a href="/pubmed/17268883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17268883</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.de_vries.2015.25">de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M, Jansen A. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. <span><span class="ref-journal">Pediatr Neurol. </span>2015;<span class="ref-vol">52</span>:25–35.</span> [<a href="/pmc/articles/PMC4427347/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4427347</span></a>] [<a href="/pubmed/25532776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25532776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.dickson.2013.1711">Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. <span><span class="ref-journal">Int J Cancer. </span>2013;<span class="ref-vol">132</span>:1711–7.</span> [<a href="/pmc/articles/PMC3558545/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3558545</span></a>] [<a href="/pubmed/22927055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22927055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.dogan.2015">Dogan V, Yesil S, Kayali S, Beken S, Ozgur S. Ertugrul I, Bozkurt C, Orun UA, Karademir S. J Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus Trop Pediatr 2015;61:74-7. [<a href="/pubmed/25344617" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25344617</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.dworakowska.2009.45">Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. <span><span class="ref-journal">Endocr Relat Cancer. </span>2009;<span class="ref-vol">16</span>:45–58.</span> [<a href="/pubmed/18978035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18978035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.eden.2014.10">Eden KE, de Vries PJ, Moss J, Richards C, Oliver C. Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers. <span><span class="ref-journal">J Neurodev Disord. </span>2014;<span class="ref-vol">6</span>:10.</span> [<a href="/pmc/articles/PMC4017702/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4017702</span></a>] [<a href="/pubmed/24822087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24822087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.elhashemite.2003.1348">El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">361</span>:1348–9.</span> [<a href="/pubmed/12711473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12711473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.elsayes.2005.80">Elsayes KM, Narra VR, Lewis JS Jr, Brown JJ. Magnetic resonance imaging of adrenal angiomyolipoma. <span><span class="ref-journal">J Comput Assist Tomogr. </span>2005;<span class="ref-vol">29</span>:80–2.</span> [<a href="/pubmed/15665688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15665688</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.ewalt.1998.141">Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion growth in children with tuberous sclerosis complex. <span><span class="ref-journal">J Urol. </span>1998;<span class="ref-vol">160</span>:141–5.</span> [<a href="/pubmed/9628635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9628635</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.farach.2017.771">Farach LS, Gibson WT, Sparagana SP, Nellist M, Stumpel CT, Hietala M, Friedman E, Pearson DA, Creighton SP, Wagemans A, Segel R, Ben-Shalom E, Au KS, Northrup H. TSC2 c.1864C&#x0003e;T variant associated with mild cases of tuberous sclerosis complex. <span><span class="ref-journal">Am J Med Genet A. </span>2017;<span class="ref-vol">173</span>:771–5.</span> [<a href="/pubmed/28211972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28211972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.floricel.2007.502">Floricel F, Higaki K, Maki H, Nanba E, Ninomiya H, Ohno K. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells. <span><span class="ref-journal">Brain Dev. </span>2007;<span class="ref-vol">29</span>:502–9.</span> [<a href="/pubmed/17376623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17376623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.fox.2017.744">Fox J, Ben-Shachar S, Uliel S, Svirsky R, Saitsu H, Matsumoto N, Fattal-Valevski A. Rare familial TSC2 gene mutation associated with atypical phenotype presentation of Tuberous Sclerosis Complex. <span><span class="ref-journal">Am J Med Genet A. </span>2017;<span class="ref-vol">173</span>:744–8.</span> [<a href="/pubmed/28127866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28127866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.franz.2001.661">Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2001;<span class="ref-vol">164</span>:661–8.</span> [<a href="/pubmed/11520734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11520734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.french.2016.2153">French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. <span><span class="ref-journal">Lancet. </span>2016;<span class="ref-vol">388</span>:2153–63.</span> [<a href="/pubmed/27613521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27613521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.fricke.2004.1027">Fricke BL, Donnelly LF, Casper KA, Bissler JJ. Frequency and imaging appearance of hepatic angiomyolipomas in pediatric and adult patients with tuberous sclerosis. <span><span class="ref-journal">AJR Am J Roentgenol. </span>2004;<span class="ref-vol">182</span>:1027–30.</span> [<a href="/pubmed/15039181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15039181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.gillberg.1994.50">Gillberg IC, Gillberg C, Ahls&#x000e9;n G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. <span><span class="ref-journal">Dev Med Child Neurol. </span>1994;<span class="ref-vol">36</span>:50–6.</span> [<a href="/pubmed/8132114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8132114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.goh.2005.235">Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:235–8.</span> [<a href="/pubmed/16043792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16043792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.goyer.2015.450">Goyer I, Dahdah N, Major P. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. <span><span class="ref-journal">Pediatr Neurol. </span>2015;<span class="ref-vol">52</span>:450–3.</span> [<a href="/pubmed/25682485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25682485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.gupta.2017.1337_1">Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, Inoue Y, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX., ATS Assembly on Clinical Problems.  Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. an official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2017;<span class="ref-vol">196</span>:1337–48.</span> [<a href="/pmc/articles/PMC5694834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5694834</span></a>] [<a href="/pubmed/29140122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29140122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.han.2011.973">Han JM, Sahin M. TSC1/TSC2 signaling in the CNS. <span><span class="ref-journal">FEBS Lett. </span>2011;<span class="ref-vol">585</span>:973–80.</span> [<a href="/pmc/articles/PMC3070766/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3070766</span></a>] [<a href="/pubmed/21329690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21329690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.harris.2003.re15">Harris TE, Lawrence JC Jr. TOR signaling. <span><span class="ref-journal">Sci STKE. </span>2003;<span class="ref-vol">2003</span>:re15.</span> [<a href="/pubmed/14668532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14668532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.henske.2016.16035">Henske EP, J&#x000f3;&#x0017a;wiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. <span><span class="ref-journal">Nat Rev Dis Primers. </span>2016;<span class="ref-vol">2</span>:16035.</span> [<a href="/pubmed/27226234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27226234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.hoogeveenwesterveld.2012.476">Hoogeveen-Westerveld M, Ekong R, Povey S, Karbassi I, Batish SD, den Dunnen JT, van Eeghen A, Thiele E, Mayer K, Dies K, Wen L, Thompson C, Sparagana SP, Davies P, Aalfs C, van den Ouweland A, Halley D, Nellist M. Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. <span><span class="ref-journal">Hum Mutat. </span>2012;<span class="ref-vol">33</span>:476–9.</span> [<a href="/pubmed/22161988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22161988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.hoogeveenwesterveld.2013.167">Hoogeveen-Westerveld M, Ekong R, Povey S, Mayer K, Lannoy N, Elmslie F, Bebin M, Dies K, Thompson C, Sparagana SP, Davies P, van Eeghen AM, Thiele EA, van den Ouweland A, Halley D, Nellist M. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:167–75.</span> [<a href="/pubmed/22903760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22903760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.humphrey.2014.108">Humphrey A, MacLean C, Ploubidis GB, Granader Y, Clifford M, Haslop M, Neville BG, Yates JR, Bolton PF., Tuberous Sclerosis 2000 Study Group.  Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis. <span><span class="ref-journal">Epilepsia. </span>2014;<span class="ref-vol">55</span>:108–16.</span> [<a href="/pubmed/24417555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24417555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.huynh.2015.1224">Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A. Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. <span><span class="ref-journal">Mol Cancer Ther. </span>2015;<span class="ref-vol">14</span>:1224–35.</span> [<a href="/pubmed/25724664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25724664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.hwang.2016.56">Hwang SK, Lee JH, Yang J, Lim CS, Lee JA, Lee YS, Lee K, Kaang BK. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. <span><span class="ref-journal">Mol Brain. </span>2016;<span class="ref-vol">9</span>:56.</span> [<a href="/pmc/articles/PMC4878062/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4878062</span></a>] [<a href="/pubmed/27216612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27216612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.inoki.2003.1829">Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. <span><span class="ref-journal">Genes Dev. </span>2003;<span class="ref-vol">17</span>:1829–34.</span> [<a href="/pmc/articles/PMC196227/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC196227</span></a>] [<a href="/pubmed/12869586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12869586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.jansen.2006.528">Jansen AC, Sancak O, D'Agostino MD, Badhwar A, Roberts P, Gobbi G, Wilkinson R, Melanson D, Tampieri D, Koenekoop R, Gans M, Maat-Kievit A, Goedbloed M, van den Ouweland AM, Nellist M, Pandolfo M, McQueen M, Sims K, Thiele EA, Dubeau F, Andermann F, Kwiatkowski DJ, Halley DJ, Andermann E. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">60</span>:528–39.</span> [<a href="/pubmed/17120248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17120248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.jarrar.2004.479">Jarrar RG, Buchhalter JR, Raffel C. Long-term outcome of epilepsy surgery in patients with tuberous sclerosis. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">62</span>:479–81.</span> [<a href="/pubmed/14872037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14872037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.jeste.2008.520">Jeste SS, Sahin M, Bolton P, Ploubidis GB, Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. <span><span class="ref-journal">J Child Neurol. </span>2008;<span class="ref-vol">23</span>:520–5.</span> [<a href="/pubmed/18160549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18160549</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.jeste.2016.766">Jeste SS, Varcin KJ, Hellemann GS, Gulsrud AC, Bhatt R, Kasari C, Wu JY, Sahin M, Nelson CA. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. <span><span class="ref-journal">Neurology. </span>2016;<span class="ref-vol">87</span>:766–72.</span> [<a href="/pmc/articles/PMC4999317/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4999317</span></a>] [<a href="/pubmed/27440144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27440144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.johnson.2002.458">Johnson SR, Clelland CA, Ronan J, Tattersfield AE, Knox AJ. The TSC-2 product tuberin is expressed in lymphangioleiomyomatosis and angiomyolipoma. <span><span class="ref-journal">Histopathology. </span>2002;<span class="ref-vol">40</span>:458–63.</span> [<a href="/pubmed/12010366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12010366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.joinson.2003.335">Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. <span><span class="ref-journal">Psychol Med. </span>2003;<span class="ref-vol">33</span>:335–44.</span> [<a href="/pubmed/12622312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12622312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.jones.1999.1305">Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, Sampson JR, Cheadle JP. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:1305–15.</span> [<a href="/pmc/articles/PMC1377866/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377866</span></a>] [<a href="/pubmed/10205261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10205261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kagawa.2005.429">Kagawa K, Chugani DC, Asano E, Juh&#x000e1;sz C, Muzik O, Shah A, Shah J, Sood S, Kupsky WJ, Mangner TJ, Chakraborty PK, Chugani HT. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET). <span><span class="ref-journal">J Child Neurol. </span>2005;<span class="ref-vol">20</span>:429–38.</span> [<a href="/pubmed/15971355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15971355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.khare.2001.347">Khare L, Strizheva GD, Bailey JN, Au KS, Northrup H, Smith M, Smalley SL, Henske EP. A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:347–9.</span> [<a href="/pmc/articles/PMC1734876/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734876</span></a>] [<a href="/pubmed/11403047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11403047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kilincaslan.2017.383">Kilincaslan A, Kok BE, Tekturk P, Yalcinkaya C, Ozkara C, Yapici Z. Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex. <span><span class="ref-journal">J Child Adolesc Psychopharmacol. </span>2017;<span class="ref-vol">27</span>:383–8.</span> [<a href="/pubmed/27797585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27797585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kingswood.2017.2">Kingswood JC, d&#x02019;Aug&#x000e8;res GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O&#x02019;Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonneberg B, Jansen AC. TuberOus SClerosis registry to increase disease Awareness (TOSCA)&#x02013;baseline data on 2093 patients. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2017;<span class="ref-vol">12</span>:2.</span> [<a href="/pmc/articles/PMC5217262/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5217262</span></a>] [<a href="/pubmed/28057044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28057044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.knox.2007.e375">Knox S, Ge H, Dimitroff BD, Ren Y, Howe KA, Arsham AM, Easterday MC, Neufeld TP, O'Connor MB, Selleck SB. Mechanisms of TSC-mediated control of synapse assembly and axon guidance. <span><span class="ref-journal">PLoS One. </span>2007;<span class="ref-vol">2</span>:e375.</span> [<a href="/pmc/articles/PMC1847706/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1847706</span></a>] [<a href="/pubmed/17440611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17440611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kobashi.2008.1076">Kobashi Y, Sugui T, Irei T, Nakata M, Oka M. Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. <span><span class="ref-journal">Respirology. </span>2008;<span class="ref-vol">13</span>:1076–81.</span> [<a href="/pubmed/18699800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18699800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kopp.2008.505">Kopp CM, Muzykewicz DA, Staley BA, Thiele EA, Pulsifer MB. Behavior problems in children with tuberous sclerosis complex and parental stress. <span><span class="ref-journal">Epilepsy Behav. </span>2008;<span class="ref-vol">13</span>:505–10.</span> [<a href="/pubmed/18602868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18602868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kothare.2014.1025">Kothare SV, Singh K, Chalifoux JR, Staley BA, Weiner HL, Menzer K, Devinsky O. Severity of manifestations in tuberous sclerosis complex in relation to genotype. <span><span class="ref-journal">Epilepsia. </span>2014;<span class="ref-vol">55</span>:1025–9.</span> [<a href="/pubmed/24917535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24917535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kozlowski.2007.389">Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, Au KS, Lazarus R, Domanska-Pakiela D, Kotulska K, Jozwiak S, Kwiatkowski DJ. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. <span><span class="ref-journal">Hum Genet. </span>2007;<span class="ref-vol">121</span>:389–400.</span> [<a href="/pubmed/17287951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17287951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kozma.2002.65">Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. <span><span class="ref-journal">Bioessays. </span>2002;<span class="ref-vol">24</span>:65–71.</span> [<a href="/pubmed/11782951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11782951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.krueger.2013.618">Krueger DA. Management of CNS-related disease manifestations in patients with tuberous sclerosis complex. <span><span class="ref-journal">Curr Treat Options Neurol. </span>2013;<span class="ref-vol">15</span>:618–33.</span> [<a href="/pubmed/23852707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23852707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.krueger.2010.1801">Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">363</span>:1801–11.</span> [<a href="/pubmed/21047224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21047224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.krueger.a">Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. 2013a;49:255-65. [<a href="/pmc/articles/PMC4058297/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4058297</span></a>] [<a href="/pubmed/24053983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24053983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.krueger.2013b.679">Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim M-O, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. <span><span class="ref-journal">Ann Neurol. </span>2013b;<span class="ref-vol">74</span>:679–87.</span> [<a href="/pubmed/23798472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23798472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.kwiatkowski.2010">Kwiatkowski DJ. Genetics of tuberous sclerosis complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, eds. <em>Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics</em>. Weinheim: Wiley-Blackwell; 2010:29-57.</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.lamb.2000.281">Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. <span><span class="ref-journal">Nat Cell Biol. </span>2000;<span class="ref-vol">2</span>:281–7.</span> [<a href="/pubmed/10806479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10806479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.leclezio.2015.113">Leclezio L, de Vries PJ. Advances in the treatment of tuberous sclerosis complex. <span><span class="ref-journal">Curr Opin Psychiatry. </span>2015;<span class="ref-vol">28</span>:113–20.</span> [<a href="/pubmed/25602245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25602245</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.lee.2007.440">Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. <span><span class="ref-journal">Cell. </span>2007;<span class="ref-vol">130</span>:440–55.</span> [<a href="/pubmed/17693255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17693255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.lennert.2013.461">Lennert B, Farrelly E, Sacco P, Pira G, Frost M. Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. <span><span class="ref-journal">J Child Neurol. </span>2013;<span class="ref-vol">28</span>:461–9.</span> [<a href="/pubmed/22772159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22772159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.lewis.2013.1526">Lewis WW, Sahin M, Scherrer B, Peters JM, Suarez RO, Vogel-Farley VK, Jeste SS, Gregas MC, Prabhu SP, Nelson CA 3rd, Warfield SK. Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders. <span><span class="ref-journal">Cereb Cortex. </span>2013;<span class="ref-vol">23</span>:1526–32.</span> [<a href="/pmc/articles/PMC3673171/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3673171</span></a>] [<a href="/pubmed/22661408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22661408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.li.2013.588">Li LH, Li N, Zhao JY, Fei P, Zhang GM, Mao JB, Rychwalski PJ. Findings of perinatal ocular examination performed on 3573, healthy full-term newborns. <span><span class="ref-journal">Br J Ophthalmol. </span>2013;<span class="ref-vol">97</span>:588–91.</span> [<a href="/pmc/articles/PMC3632968/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3632968</span></a>] [<a href="/pubmed/23426739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23426739</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.li.2004.32">Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. <span><span class="ref-journal">Trends Biochem Sci. </span>2004;<span class="ref-vol">29</span>:32–8.</span> [<a href="/pubmed/14729330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14729330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mak.2004.588">Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. <span><span class="ref-journal">Cancer Invest. </span>2004;<span class="ref-vol">22</span>:588–603.</span> [<a href="/pubmed/15565817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15565817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.martignoni.2002.198">Martignoni G, Bonetti F, Pea M, Tardanico R, Brunelli M, Eble JN. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome. <span><span class="ref-journal">Am J Surg Pathol. </span>2002;<span class="ref-vol">26</span>:198–205.</span> [<a href="/pubmed/11812941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11812941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mayer.2004.e64">Mayer K, Goedbloed M, van Zijl K, Nellist M, Rott HD. Characterization of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:e64.</span> [<a href="/pmc/articles/PMC1735780/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735780</span></a>] [<a href="/pubmed/15121792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15121792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mccormack.2016.748">McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J., ATS/JRS Committee on Lymphangioleiomyomatosis.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2016;<span class="ref-vol">194</span>:748–61.</span> [<a href="/pmc/articles/PMC5803656/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5803656</span></a>] [<a href="/pubmed/27628078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27628078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mccormack.2011.1595">McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC., National Institutes of Health Rare Lung Diseases Consortium.  MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1595–606.</span> [<a href="/pmc/articles/PMC3118601/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3118601</span></a>] [<a href="/pubmed/21410393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21410393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mccormack.2008.507">McCormack FX. Lymphangioleiomyomatosis: a clinical update. <span><span class="ref-journal">Chest. </span>2008;<span class="ref-vol">133</span>:507–16.</span> [<a href="/pubmed/18252917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18252917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mcdonald.2017.1981">McDonald NM, Varcin KJ, Bhatt R, Wu JY, Sahin M, Nelson CA, Jeste SS. Early autism symptoms in infants with tuberous sclerosis complex. <span><span class="ref-journal">Autism Research. </span>2017;<span class="ref-vol">10</span>:1981–1990.</span> [<a href="/pubmed/28801991" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28801991</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mlczoch.2015.618">Mlczoch E, Hanslik A, Luckner D, Kitzm&#x000fc;ller E, Prayer D, Michel-Behnke I. Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus. <span><span class="ref-journal">Ultrasound Obstet Gynecol. </span>2015;<span class="ref-vol">45</span>:618–21.</span> [<a href="/pubmed/24913039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24913039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mourikis.1999.153">Mourikis D, Chatziioannou A, Antoniou A, Kehagias D, Gikas D, Vlahos L. Selective arterial embolization in the management of symptomatic renal angiomyolipomas. <span><span class="ref-journal">Eur J Radiol. </span>1999;<span class="ref-vol">32</span>:153–9.</span> [<a href="/pubmed/10632551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10632551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.mozaffari.2009.88">Mozaffari M, Hoogeveen-Westerveld M, Kwiatkowski D, Sampson J, Ekong R, Povey S, den Dunnen JT, van den Ouweland A, Halley D, Nellist M. Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. <span><span class="ref-journal">BMC Med Genet. </span>2009;<span class="ref-vol">10</span>:88.</span> [<a href="/pmc/articles/PMC2753308/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2753308</span></a>] [<a href="/pubmed/19747374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19747374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.muzykewicz.2007.506">Muzykewicz DA, Newberry P, Danforth N, Halpern EF, Thiele EA. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. <span><span class="ref-journal">Epilepsy Behav. </span>2007;<span class="ref-vol">11</span>:506–13.</span> [<a href="/pubmed/17936687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17936687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.muzykewicz.2009.465">Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:465–8.</span> [<a href="/pubmed/19419980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19419980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.nellist.2015.10">Nellist M, Brouwer RW, Kockx CE, van Veghel-Plandsoen M, Withagen-Hermans C, Prins-Bakker L, Hoogeveen-Westerveld M, Mrsic A, van den Berg MM, Koopmans AE, de Wit MC, Jansen FE, Maat-Kievit AJ, van den Ouweland A, Halley D, de Klein A, van IJcken WF. Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. <span><span class="ref-journal">BMC Med Genet. </span>2015;<span class="ref-vol">16</span>:10.</span> [<a href="/pmc/articles/PMC4422413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4422413</span></a>] [<a href="/pubmed/25927202" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25927202</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.nellist.2009.319">Nellist M, van den Heuvel D, Schluep D, Exalto C, Goedbloed M, Maat-Kievit A, van Essen T, van Spaendonck-Zwarts K, Jansen F, Helderman P, Bartalini G, Vierimaa O, Penttinen M, van den Ende J, van den Ouweland A, Halley D. Missense mutations to the TSC1 gene cause tuberous sclerosis complex. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:319–28.</span> [<a href="/pmc/articles/PMC2986174/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986174</span></a>] [<a href="/pubmed/18830229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18830229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.northrup.2013.243">Northrup H, Krueger DA., International Tuberous Sclerosis Complex Consensus Group.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <span><span class="ref-journal">Pediatr Neurol. </span>2013;2013;<span class="ref-vol">49</span>:243–54.</span> [<a href="/pmc/articles/PMC4080684/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4080684</span></a>] [<a href="/pubmed/24053982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24053982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.northrup.1993.41">Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. <span><span class="ref-journal">J Med Genet. </span>1993;<span class="ref-vol">30</span>:41–3.</span> [<a href="/pmc/articles/PMC1016232/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1016232</span></a>] [<a href="/pubmed/8423606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8423606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.numis.2011.981">Numis AL, Major P, Montenegro MA, Muzykewicz DA, Pulsifer MB, Thiele EA. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. <span><span class="ref-journal">Neurology. </span>2011;<span class="ref-vol">76</span>:981–7.</span> [<a href="/pmc/articles/PMC3271577/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3271577</span></a>] [<a href="/pubmed/21403110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21403110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.oconnor.2003.409">O'Connor SE, Kwiatkowski DJ, Roberts PS, Wollmann RL, Huttenlocher PR. A family with seizures and minor features of tuberous sclerosis and a novel TSC2 mutation. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:409–12.</span> [<a href="/pubmed/12913212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12913212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.osborne.1991.125">Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. <span><span class="ref-journal">Ann N Y Acad Sci. </span>1991;<span class="ref-vol">615</span>:125–7.</span> [<a href="/pubmed/2039137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2039137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.pan.2008.387">Pan CC, Chung MY, Ng KF, Liu CY, Wang JS, Chai CY, Huang SH, Chen PC, Ho DM. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. <span><span class="ref-journal">J Pathol. </span>2008;<span class="ref-vol">214</span>:387–93.</span> [<a href="/pubmed/18085521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18085521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.patel.2005.665">Patel U, Simpson E, Kingswood JC, Saggar-Malik AK. Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. <span><span class="ref-journal">Clin Radiol. </span>2005;<span class="ref-vol">60</span>:665–73.</span> [<a href="/pubmed/16038693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16038693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.pea.1998.180">Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C, Bernstein J. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. <span><span class="ref-journal">Am J Surg Pathol. </span>1998;<span class="ref-vol">22</span>:180–7.</span> [<a href="/pubmed/9500218" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9500218</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.plank.1998.4766">Plank TL, Yeung RS, Henske EP. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. <span><span class="ref-journal">Cancer Res. </span>1998;<span class="ref-vol">58</span>:4766–70.</span> [<a href="/pubmed/9809973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9809973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.popper.1991.347">Popper HH, Juettner-Smolle FM, Pongratz MG. Micronodular hyperplasia of type II pneumocytes--a new lung lesion associated with tuberous sclerosis. <span><span class="ref-journal">Histopathology. </span>1991;<span class="ref-vol">18</span>:347–54.</span> [<a href="/pubmed/2071093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2071093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.prather.2004.666">Prather P, de Vries PJ. Behavioral and cognitive aspects of tuberous sclerosis complex. <span><span class="ref-journal">J Child Neurol. </span>2004;<span class="ref-vol">19</span>:666–74.</span> [<a href="/pubmed/15563012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15563012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.pymar.2008.2006">Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:2006–17.</span> [<a href="/pmc/articles/PMC2427143/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2427143</span></a>] [<a href="/pubmed/18397877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18397877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.qin.2010.573">Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, Camposano S, Thiele E, Franz D, Kwiatkowski DJ. Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. <span><span class="ref-journal">Hum Genet. </span>2010;<span class="ref-vol">127</span>:573–82.</span> [<a href="/pmc/articles/PMC2854849/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2854849</span></a>] [<a href="/pubmed/20165957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20165957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.rendtorff.2005.374">Rendtorff ND, Bjerregaard B, Fr&#x000f6;din M, Kjaergaard S, Hove H, Skovby F, Br&#x000f8;ndum-Nielsen K, Schwartz M., Danish Tuberous Sclerosis Group.  Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:374–83.</span> [<a href="/pubmed/16114042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16114042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.rentz.2015.435">Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, Nakagawa J, Magestro M, Prestifilippo J. Tuberous sclerosis complex: a survey of health care resource use and health burden. <span><span class="ref-journal">Pediatr Neurol. </span>2015;<span class="ref-vol">52</span>:435–41.</span> [<a href="/pubmed/25771998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25771998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.ridler.2007.261">Ridler K, Suckling J, Higgins NJ, de Vries PJ, Stephenson CM, Bolton PF, Bullmore ET. Neuroanatomical correlates of memory deficits in tuberous sclerosis complex. <span><span class="ref-journal">Cereb Cortex. </span>2007;<span class="ref-vol">17</span>:261–71.</span> [<a href="/pubmed/16603714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16603714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.romanelli.2004.239">Romanelli P, Verdecchia M, Rodas R, Seri S, Curatolo P. Epilepsy surgery for tuberous sclerosis. <span><span class="ref-journal">Pediatr Neurol. </span>2004;<span class="ref-vol">31</span>:239–47.</span> [<a href="/pubmed/15464634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15464634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.rose.1999.986">Rose VM, Au KS, Pollom G, Roach ES, Prashner HR, Northrup H. Germ-line mosaicism in tuberous sclerosis: how common? <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:986–92.</span> [<a href="/pmc/articles/PMC1377822/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377822</span></a>] [<a href="/pubmed/10090883" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10090883</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sampson.1989.28">Sampson JR, Scahill SJ, Stephenson JB, Mann L, Connor JM. Genetic aspects of tuberous sclerosis in the west of Scotland. <span><span class="ref-journal">J Med Genet. </span>1989;<span class="ref-vol">26</span>:28–31.</span> [<a href="/pmc/articles/PMC1015532/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1015532</span></a>] [<a href="/pubmed/2918523" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2918523</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sancak.2005.731">Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:731–41.</span> [<a href="/pubmed/15798777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15798777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sarma.2016.467">Sarma AK, Khandker N, Kurczewski L, Brophy GM. Medical management of epileptic seizures: challenges and solutions. <span><span class="ref-journal">Neuropsychiatr Dis Treat. </span>2016;<span class="ref-vol">12</span>:467–85.</span> [<a href="/pmc/articles/PMC4771397/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4771397</span></a>] [<a href="/pubmed/26966367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26966367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sato.2002.20">Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. <span><span class="ref-journal">J Hum Genet. </span>2002;<span class="ref-vol">47</span>:20–8.</span> [<a href="/pubmed/11829138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11829138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.shepherd.1991.792">Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. <span><span class="ref-journal">Mayo Clin Proc. </span>1991;<span class="ref-vol">66</span>:792–6.</span> [<a href="/pubmed/1861550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1861550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.shields.2004.139">Shields JA, Eagle RC Jr, Shields CL, Marr BP. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. <span><span class="ref-journal">Trans Am Ophthalmol Soc. </span>2004;<span class="ref-vol">102</span>:139–47.</span> [<a href="/pmc/articles/PMC1280094/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1280094</span></a>] [<a href="/pubmed/15747752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15747752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.smolarek.1998.810">Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:810–5.</span> [<a href="/pmc/articles/PMC1377043/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377043</span></a>] [<a href="/pubmed/9529362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9529362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sj_dahl.2011.e18583">Sj&#x000f6;dahl G, Lauss M, Gudjonsson S, Liedberg F, Halld&#x000e9;n C, Chebil G, M&#x000e5;nsson W, H&#x000f6;glund M, Lindgren D. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e18583.</span> [<a href="/pmc/articles/PMC3077383/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3077383</span></a>] [<a href="/pubmed/21533174" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21533174</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.spurling_jeste.2014.160">Spurling Jeste S, Wu JY, Senturk D, Varcin K, Ko J, McCarthy B, Shimizu C, Dies K, Vogel-Farley V, Sahin M, Nelson CA 3rd. Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:160–8.</span> [<a href="/pmc/articles/PMC4117170/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4117170</span></a>] [<a href="/pubmed/24920850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24920850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.staley.2008.650">Staley BA, Montenegro MA, Major P, Muzykewicz DA, Halpern EF, Kopp CM, Newberry P, Thiele EA. Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients. <span><span class="ref-journal">Epilepsy Behav. </span>2008;<span class="ref-vol">13</span>:650–3.</span> [<a href="/pubmed/18703161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18703161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.strizheva.2001.253">Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2001;<span class="ref-vol">163</span>:253–8.</span> [<a href="/pubmed/11208653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11208653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.sun.2013.2135">Sun W, Zhu YJ, Wang Z, Zhong Q, Gao F, Lou J, Gong W, Xu W. Crystal structure of the yeast TSC1 core domain and implications for tuberous sclerosis pathological mutations. <span><span class="ref-journal">Nat Commun. </span>2013;<span class="ref-vol">4</span>:2135.</span> [<a href="/pubmed/23857276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23857276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.tierney.2011.437">Tierney KM, McCartney DL, Serfontein JR, de Vries PJ. Neuropsychological attention skills and related behaviours in adults with tuberous sclerosis complex. <span><span class="ref-journal">Behav Genet. </span>2011;<span class="ref-vol">41</span>:437–44.</span> [<a href="/pubmed/21191642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21191642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.tyburczy.2015">Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, Sahin M, Kwiatkowski DJ. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015 Nov 5;11(11):e1005637. doi: 10.1371/journal.pgen.1005637. eCollection 2015 Nov. PubMed PMID: 26540169; PubMed Central PMCID: PMC4634999. [<a href="/pmc/articles/PMC4634999/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4634999</span></a>] [<a href="/pubmed/26540169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26540169</span></a>] [<a href="http://dx.crossref.org/10.1371/journal.pgen.1005637" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CrossRef</a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.van_eeghen.2012.510">van Eeghen AM, Black ME, Pulsifer MB, Kwiatkowski DJ, Thiele EA. Genotype and cognitive phenotype of patients with tuberous sclerosis complex. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:510–5.</span> [<a href="/pmc/articles/PMC3330219/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3330219</span></a>] [<a href="/pubmed/22189265" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22189265</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.van_slegtenhorst.1998.1053">van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:1053–7.</span> [<a href="/pubmed/9580671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9580671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.vanderhooft.1996.355">Vanderhooft SL, Francis JS, Pagon RA, Smith LT, Sybert VP. Prevalence of hypopigmented macules in a healthy population. <span><span class="ref-journal">J Pediatr. </span>1996;<span class="ref-vol">129</span>:355–61.</span> [<a href="/pubmed/8804323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8804323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.webb.1991.417">Webb DW, Osborne JP. Non-penetrance in tuberous sclerosis. <span><span class="ref-journal">J Med Genet. </span>1991;<span class="ref-vol">28</span>:417–9.</span> [<a href="/pmc/articles/PMC1016911/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1016911</span></a>] [<a href="/pubmed/1870099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1870099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.weiner.2006.1494">Weiner HL, Carlson C, Ridgway EB, Zaroff CM, Miles D, LaJoie J, Devinsky O. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. <span><span class="ref-journal">Pediatrics. </span>2006;<span class="ref-vol">117</span>:1494–502.</span> [<a href="/pubmed/16651302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16651302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.wentink.2012.453">Wentink M, Nellist M, Hoogeveen-Westerveld M, Zonnenberg B, van der Kolk D, van Essen T, Park SM, Woods G, Cohn-Hokke P, Brussel W, Smeets E, Brooks A, Halley D, van den Ouweland A, Maat-Kievit A. Functional characterization of the TSC2 c.3598C&#x0003e;T (p.R1200W) missense mutation that co-segregates with tuberous sclerosis complex in mildly affected kindreds. <span><span class="ref-journal">Clin Genet. </span>2012;2012;<span class="ref-vol">81</span>:453–61.</span> [<a href="/pubmed/21332470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21332470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.wilde.2017.119">Wilde L, Eden K, de Vries P, Moss J, Welham A, Oliver C. Self-injury and aggression in adults with tuberous sclerosis complex: Frequency, associated person characteristics, and implications for assessment. <span><span class="ref-journal">Research in Developmental Disabilities. </span>2017;<span class="ref-vol">64</span>:119–30.</span> [<a href="/pubmed/28411579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28411579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.wong.2006.199">Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. <span><span class="ref-journal">J Child Neurol. </span>2006;<span class="ref-vol">21</span>:199–204.</span> [<a href="/pubmed/16901420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16901420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.woodford.2017.3650">Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. <span><span class="ref-journal">EMBO J. </span>2017;<span class="ref-vol">36</span>:3650–65.</span> [<a href="/pmc/articles/PMC5730846/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5730846</span></a>] [<a href="/pubmed/29127155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29127155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.xiao.1997.6097">Xiao GH, Shoarinejad F, Jin F, Golemis EA, Yeung RS. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:6097–100.</span> [<a href="/pubmed/9045618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9045618</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.yang.2014.895">Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y, Jiang Z, Oliva E, Jozwiak S, Nussbaum RL, Feldman AS, Paul E, Thiele EA, Yu JJ, Henske EP, Kwiatkowski DJ, Young RH, Wu CL. Renal cell carcinoma in tuberous sclerosis complex. <span><span class="ref-journal">Am J Surg Pathol. </span>2014;<span class="ref-vol">38</span>:895–909.</span> [<a href="/pmc/articles/PMC4139167/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4139167</span></a>] [<a href="/pubmed/24832166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24832166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.yeung.2003.368">Yeung RS. Multiple roles of the tuberous sclerosis complex genes. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2003;<span class="ref-vol">38</span>:368–75.</span> [<a href="/pubmed/14566857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14566857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tuberous-sclerosis.REF.zhang.2013.1186">Zhang J, Kim J, Alexander A, Cai S, Tripathi DN, Dere R, Tee AR, Tait-Mulder J, Di Nardo A, Han JM, Kwiatkowski E, Dunlop EA, Dodd KM, Folkerth RD, Faust PL, Kastan MB, Sahin M, Walker CL. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. <span><span class="ref-journal">Nat Cell Biol. </span>2013;<span class="ref-vol">15</span>:1186–96.</span> [<a href="/pmc/articles/PMC3789865/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3789865</span></a>] [<a href="/pubmed/23955302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23955302</span></a>]</div></li></ul></div></div><div id="tuberous-sclerosis.Chapter_Notes"><h2 id="_tuberous-sclerosis_Chapter_Notes_">Chapter Notes</h2><div id="tuberous-sclerosis.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 July 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 September 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 November 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 May 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 December 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 September 2004 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> clinically available for <i>TSC2</i> deletions</div></li><li class="half_rhythm"><div>29 August 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 December 2002 (bp) Revisions</div></li><li class="half_rhythm"><div>18 April 2001 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 July 1999 (pb) Review posted live</div></li><li class="half_rhythm"><div>5 February 1999 (hn) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1220</span><span class="label">PMID: <a href="/pubmed/20301399" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301399</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/spg20/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tubulin-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1220&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1220/?report=reader">PubReader</a></li><li><a href="/books/NBK1220/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1220" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1220" style="display:none" title="Cite this Page"><div class="bk_tt">Northrup H, Koenig MK, Pearson DA, et al. Tuberous Sclerosis Complex. 1999 Jul 13 [Updated 2018 Jul 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1220/pdf/Bookshelf_NBK1220.pdf">PDF version of this page</a> (584K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#tuberous-sclerosis.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#tuberous-sclerosis.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#tuberous-sclerosis.Clinical_Characterist" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#tuberous-sclerosis.Genetically_Related_A" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#tuberous-sclerosis.Differential_Diagnosi" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#tuberous-sclerosis.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#tuberous-sclerosis.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#tuberous-sclerosis.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#tuberous-sclerosis.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#tuberous-sclerosis.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#tuberous-sclerosis.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3458[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">IFNG</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7248[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TSC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7249[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TSC2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1488118" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1488118" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1488118" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1488118" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28057044" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.</a><span class="source">[Orphanet J Rare Dis. 2017]</span><div class="brieflinkpop offscreen_noflow">TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2017 Jan 5; 12(1):2. Epub 2017 Jan 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301636" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Von Hippel-Lindau Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Von Hippel-Lindau Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">van Leeuwaarde RS, Ahmad S, Links TP, Giles RH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301510" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dietz H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27698899" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?</a><span class="source">[J Cancer. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Habib SL, Al-Obaidi NY, Nowacki M, Pietkun K, Zegarska B, Kloskowski T, Zegarski W, Drewa T, Medina EA, Zhao Z, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Cancer. 2016; 7(12):1621-1631. Epub 2016 Jul 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28414661" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Delayed Presentation of Tuberour Sclerosis Complex in Adult Women.</a><span class="source">[J La State Med Soc. 2017]</span><div class="brieflinkpop offscreen_noflow">Delayed Presentation of Tuberour Sclerosis Complex in Adult Women.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Manalac J, Sadd S, Akoghlanian G, Benoit-Clark T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J La State Med Soc. 2017 Mar-Apr; 169(2):46. Epub 2017 Apr 15.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301399" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301399" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040cc439a66ee2ba4f1b7b">Tuberous Sclerosis Complex - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Tuberous Sclerosis Complex - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:28:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88BE0BE03F9B7100000000071E0291&amp;ncbi_session=CE88BE0BE040CC41_1822SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1220%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1220&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1220/&amp;ncbi_pagename=Tuberous Sclerosis Complex - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88BE0BE040CC41_1822SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>